abstracts

0
Rate this post

Feuillet précédente

Abstracts Lille 2003

Exemple comparution Lunette N° Rassemblement N°contagion Auteurs Armoiries Adresses
Orale Lundi 14/04    1 O1 H Bourgoin (1); C Le Guellec (1); F Mentré (2); M Büchler (3); P Marquet (4); Y Lebranchu (3); E Autret-Leca (1); G Paintaud (1); BAYESIAN ESTIMATION OF CYCLOSPORINE AREA UNDER THE CURVE IN RENAL TRANSPLANT PATIENTS
Abstract effectué
(1) Department of pharmacology, University hospital, TOURS; (2) Department of epidemiology and biostatistics, Bichat hospital, PARIS; (3) Department of nephrology and clinical immunology, University hospital, TOURS; (4) Department of pharmacology and toxicology, University hospital, LIMOGES;
Orale Lundi 14/04    1 O10 K Brendel (1); M Legrand (1); C Goujard (2); AM Taburet (3); B Diquet (4); F Mentré (1); ET Cophar1-Anrs102 study group (5); POPULATION PHARMACOKINETIC ANALYSIS OF INDINAVIR IN HIV CONTROLLED PATIENTS UNDER STABLE REGIMEN
Abstract effectué
(1) DEBRC, Hosto Bichat, PARIS; (2) Maladies Infectieuses, Hosto Bicêtre, KREMLIN-BICÊTRE; (3) Remède, Hosto Bicêtre, KREMLIN-BICÊTRE; (4) Pharmacologie-Toxicologie, CHU Angers, ANGERS; (5) AC5, ANRS, PARIS;
Orale Lundi 14/04    1 O2 M Legrand (1); C Goujard (2); F Mentré (1); B Diquet (3); AM Taburet (4); ET Cophar1-Anrs102 study group (5); NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS PLASMA CONCENTRATIONS IN PATIENTS WITH SUSTAINED VIROLOGICAL RESPONSE ON HAART
Abstract effectué
(1) DEBRC, Hosto Bichat, PARIS; (2) Maladies Infectieuses, Hosto Bicêtre, KREMLIN-BICÊTRE; (3) Pharmacologie-Toxicologie, CHU Angers, ANGERS; (4) Remède, Hosto Bicêtre, KREMLIN-BICÊTRE; (5) AC5, ANRS, PARIS;
Orale Lundi 14/04    1 O3 JM Tréluyer (1); JP Morini (2); J Dimet (1); I Gorin (2); E Rey (1); J Deleuze (2); PF Ceccaldi (1); JP Escande (2); G Pons (1); N Dupin (2); HIGH CONCENTRATIONS OF NELFINAVIR AS AN INDEPENDENT RISK FACTOR FOR LIPODYSTROPHY IN HIV-INFECTED PATIENTS
Abstract effectué
(1) Pharmacologie, Hosto Cochin Heureux Vincent de Paul, PARIS; (2) Dermatologie, Hosto Cochin Heureux Vincent de Paul, PARIS;
Orale Lundi 14/04    1 O4 H Chappuy (1); JM Treluyer (1); J Dimet (1); G Firtion (2); E Rey (1); M Foucher (2); G Pons (1); L Mandelbrot (3); MATERNAL-FETAL TRANSFER AND AMNIOTIC FLUID ACCUMULATION FLUID ACCUMULATION OF ANTIRETROVIRAL DRUGS IN HIV INFECTED PREGNANT WOMEN
Abstract effectué
(1) Pharmacologie, Hosto Cochin Heureux Vincent de Paul, PARIS; (2) Gynécologie, Hosto Cochin Heureux Vincent de Paul, PARIS; (3) Gynécologie, Hosto Paillette Mourier, COLOMBES;
Orale Lundi 14/04    1 O5 B Guillet (1); N Simon (2); J Sampol (1); Y Berland (1); B Dussol (1); P Brunet (1); POPULATION PHARMACOKINETICS OF ENOXAPARIN IN HAEMODIALYZED PATIENTS
Abstract effectué
(1) Faveur de urologie, Hosto de la exécution, MARSEILLE; (2) Ouvroir de Pharmacologie médicale et dispensaire, Compréhension de médicament, MARSEILLE;
Orale Lundi 14/04    1 O6 JS Hulot (1); C Vantelon (1); A Ankri (2); G Montalescot (3); PH Lechat (1); POPULATION PHARMACOKINETICS OF THE LOW MOLECULAR WEIGHT HEPARIN ENOXAPARIN IN ELDERLY OR PATIENTS WITH RENAL FAILURE ADMITTED IN CARDIOLOGY INTENSIVE CARE UNIT
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Compassion-Salpétrière, PARIS; (2) Ouvroir d’coagulation, Hosto Compassion-Salpétrière, PARIS; (3) Faveur de Cardiologie, Hosto Compassion-Salpétrière, PARIS;
Orale Lundi 14/04    1 O7 A Prémaud (1); J Debord (1); A Rousseau (1); Y Le Meur (2); O Toupance (3); G Hoizey (4); P Marquet (1); EVOLUTION OF THE PHARMACOKINETICS OF MYCOPHENOLIC ACID WITH POST-TRANSPLANTATION DELAY IN RENAL TRANSPLANT RECIPIENTS
Abstract effectué
(1) Pharmacologie et Toxicologie, CHU, LIMOGES; (2) Urologie, CHU, LIMOGES; (3) Urologie et Hémodialyse, CHU, REIMS; (4) Pharmacologie et Toxicologie, CHU, REIMS;
Orale Lundi 14/04    1 O8 F Heureux-Marcoux (1); A Rousseau (1); Y Le Meur (2); O Toupance (3); G Hoizey (4); J Debord (1); P Marquet (1); EVOLUTION OF CYCLOSPORINE (CSA) PHARMACOKINETICS WITHIN THE FIRST MONTH AFTER RENAL TRANSPLANTATION : PRELIMINARY RESULTS OF A BI-CENTER CLINICAL STUDY
Abstract effectué
(1) Pharmacologie et Toxicologie, CHU, LIMOGES; (2) Urologie, CHU, LIMOGES; (3) Urologie et Hémodialyse, CHU, REIMS; (4) Pharmacologie et Toxicologie, CHU, REIMS;
Orale Lundi 14/04    1 O9 A Liutkus (1); M Popon (1); C Loirat (2); P Cochat (3); E Jacqz-Aigrain (1); OPTIMIZING CYCLOSPORINE MONITORING IN PAEDIATRIC RENAL TRANSPLANTED PATIENTS
Abstract effectué
(1) Pharmacologie Pédiatrique – Pharmacogénétique, Hosto Lolo Debré, PARIS; (2) Urologie Pédiatrique, Hosto Lolo Debré, PARIS; (3) Urologie Pédiatrique, Hosto Edouard Herriot, LYON;
Orale Lundi 14/04    2 O11 MN Beyens (1); C Guy (1); M Ratrema (1); G Mounier (1); M Ollagnier (1); FRENCH NATIONAL MONITORING PROGRAMME AFTER ONE YEAR OF ZYBAN
Abstract effectué
(1) Foyer de Pharmacovigilance, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE;
Orale Lundi 14/04    2 O12 C Le Beller (1); S Henry (1); M Hausse (2); G Derrien (3); C Le Maignan (4); E Levy (4); B Bonan (2); A Lillo-Le Louët (1); ASSESSMENT AFTER 12-MONTHS OF SYSTEMATIC REPORT OF CANCER TREATMENT ADVERSE DRUG REACTIONS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Hosto Occidental Georges Pompidou, PARIS; (2) Remède, Hosto Occidental Georges Pompidou, PARIS; (3) Cancérologie-Radiologie, Hosto Occidental Georges Pompidou, PARIS; (4) Cancérologie Médicale, Hosto Occidental Georges Pompidou, PARIS;
Orale Lundi 14/04    2 O13 ML Laroche (1); M Amaniou (1); O Chaput (1); Y Nouaille (1); L Montagnard (1); CONSUMERS ASSOCIATION AND MEDICAL REPORTS ON CERIVASTATIN-INDUCED MUSCLE DISORDERS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, CHU Dupuytren, LIMOGES;
Orale Lundi 14/04    2 O14 R Serreau (1); A Liutkus (1); F Menez (2); V Baudouin (3); D Luton (4); E Jacqz-Aigrain (1); ADVERSE EFFECTS OF ACE INHIBITORS AND AT1 RECEPTOR BLOCKERS DURING PREGNANCY
Abstract effectué
(1) Pharmacology Unit, Lolo Debré Hospital, PARIS; (2) Foetopathology unit, Lolo Debré Hospital, PARIS; (3) Nephrology Unit, Lolo Debré Hospital, PARIS; (4) Gynecology-Obstetrics Unit, Lolo Debré Hospital, PARIS;
Orale Lundi 14/04    2 O15 H Saissi (1); AP Jonville-Bera (1); F Artistique-Salinas (1); G Grisette (2); E Autret-Leca (1); DRUG-INDUCED ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, CHRU Tours, TOURS; (2) Faveur de Dermatologie, CHRU, TOURS;
Orale Lundi 14/04    2 O16 K Martin (1); S Lawson-Ayayi (2); G Miremont-Salamé (1); MJ Blaizeau (3); D Lacoste (3); M Dupon (3); T Schaverberke (4); P Mercié (3); JM Ragnaud (3); F Haramburu (1); F Dabis (2); ASEPTIC OSTEONECROSIS IN HIV-INFECTED PATIENTS, AQUITAINE COHORT 1999 – 2002
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Préfecture de Pharmacologie, Séminaire Victor Segalen, CHU, BORDEAUX; (2) INSERM U330, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (3) Foyer d’Nouvelle et de Médicament sur l’Immunodéficience Bonne, CHU, BORDEAUX; (4) Faveur de Rhumatologie, CHU, BORDEAUX;
Orale Lundi 14/04    2 O17 S Lugardon (1); K Desboeuf (2); P Fernet (2); JL Montastruc (1); M Lapeyre-Mestre (1); ASSESSING THE PREVALENCE OF ADVERSE DRUG REACTIONS IN A FRENCH UNIVERSITY HOSPITAL : A CAPTURE-RECAPTURE STUDY USING DATA FROM PMSI AND THE FRENCH PHARMACOVIGILANCE DATABASE
Abstract effectué
(1) Faveur de Pharmacologie Asile, Compréhension de Purge, TOULOUSE; (2) Ligue d’Infographie Médicale et d’Evaluation, CHU, TOULOUSE;
Orale Lundi 14/04    2 O18 G Pietri (1); E Van Cordon On Behalf Of The Euro-Med-Stat Group (1); EURO-MED-STAT: MONITORING EXPENDITURE AND UTILISATION OF MEDICINAL PRODUCTS IN THE EUROPEAN UNION COUNTRIES. A PUBLIC HEALTH APPROACH
Abstract effectué
(1) Union de Pharmacoépidémiologie, Foyer Abordable Étudiant Lyon Sud, PIERRE-BENITE;
Orale Lundi 14/04    2 O19 P Mismetti (1); JM Yeguiayan (1); S Quenet (1); B Tardy (2); S Laporte (1); H Decousus (1); PHARMACOEPIDEMIOLOGY OF INITIAL ANTICOAGULANT THERAPY OF DEEP-VEIN THROMBOSIS: RISK ASSESSMENT OF MAJOR HAEMORRHAGES BASED ON INDIVIDUAL DATA FROM 5 RANDOMISED TRIALS
Abstract effectué
(1) Union Pharmacologie Asile, EA3065, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (2) Faveur Urgences et Ranimation Médicale, EA3065, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE;
Orale Lundi 14/04    2 O20 E Rahme (1); AN Barkun (2); YM Toubouti (1); M Bardou (2); SPECIFIC COX-2 INHIBITORS ROFECOXIB AND CELECOXIB MAY PREVENT COLORECTAL ADENOMAS OCCURRENCE AND RECURRENCE. A NESTED CASE-CONTROL STUDY
Abstract effectué
(1) Clinical Epidemiology Unit, McGill University Health Center, MONTREAL, CANADA; (2) Gastroenterology Department, McGill University Health Center, MONTREAL, CANADA;
Orale Mardi 15/04    7 O80 F Moritz (1); M Isabelle (1); C Monteil (1); F Bauer (1); P Mulder (1); V Richard (1); C Thuillez (1); ENHANCED OXIDATIVE STRESS AS A POTENTIAL MECHANISM UNDERLYING THE COCAINE-INDUCED CARDIAC DYSFUNCTION : PREVENTIVE EFFECT OF VITAMINS C AND E
Abstract effectué
(1) INSERM E9920, Compréhension de médicament, ROUEN;
Orale Mardi 15/04    7 O81 F Dupuis (1); P Limiñana (1); J Atkinson (1); JM Chillon (1); CAPTOPRIL ATTENUATES CEREBRAL ARTERIOLAR REMODELING AND DECREASES THE LOWER LIMIT OF CEREBRAL BLOOD FLOW AUTOREGULATION IN OLD SHR
Abstract effectué
(1) Ouvroir de pharmacologie cardiovasculaire (EA3448), Compréhension de Remède, NANCY;
Orale Mardi 15/04    7 O82 R Tissier (1); K Aouam (1); A Berdeaux (1); B Ghaleh (1); PHARMACOLOGICAL DELAYED PRECONDITIONING AGAINST MYOCARDIAL INFARCTION: EVIDENCE FOR A “CEILING OF CARDIOPROTECTION”
Abstract effectué
(1) Ouvroir de Pharmacologie et INSERM E 00.01, Compréhension de Purge Paris Sud, LE KREMLIN-BICETRE;
Orale Mardi 15/04    7 O83 S Pons (1); AA Hagege (2); P Meneton (2); JF Giudicelli (1); F Alhenc-Gelas (2); C Richer (1); PROTECTIVE ROLE OF THE KALLIKREIN-KININ SYSTEM IN POST-ISCHEMIC CONGESTIVE HEART FAILURE IN MICE
Abstract effectué
(1) Ouvroir de Pharmacologie et INSERM E 00.01, Compréhension de Purge Paris Sud, LE KREMLIN-BICETRE; (2) INSERM U367, Rue du Fer à Maillotin, PARIS;
Orale Mardi 15/04    7 O84 M Billing-Grima (1); J Anjuere (1); J Steger (1); C Bourdenet-Coquard (1); JL Imbs (2); INTERNALIZATION OF ANGIOTENSIN II IN THE KIDNEYS IN HYPERTENSIVE TWO-KIDNEY, ONE-CLIP RATS
Abstract effectué
(1) Université de Pharmacologie, Compréhension de Purge Séminaire Paillette Pastoureau, STRASBOURG; (2) Faveur d’Hypertension, Maladies Vasculaires et Pharmacologie Asile, Hospices Universitaires de Strasbourg, STRASBOURG;
Orale Mardi 15/04    7 O85 L Monassier (1); C Bellocq (2); J Weissenburger (3); H Greney (1); D Zimmermann (1); JD Ehrardt (1); I Baro (2); P Bousquet (1); INVOLVEMENT OF MYOCARDIAL SIGMA-2 RECEPTORS IN CARDIAC REPOLARIZATION
Abstract effectué
(1) Ouvroir de Neurobiologie et Pharmacologie Cardiovasculaire, Compréhension de Purge, STRASBOURG; (2) INSERM U533, Hosto Arrêt-Logos, NANTES; (3) Ouvroir de Pharmacologie, Hosto Heureux-Antoine, PARIS;
Orale Mardi 15/04    7 O86 C Loichot (1); L Jesel (1); A Tabernero (1); K Schoonjans (2); G Roul (1); 1I Carpusca (1); J Auwerx (2); R Andriantsitohaina (1); DELETION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA TRIGGERS A CARDIOMYOPATHY WITH AN INCREASED SUCEPTIBILITY TO MYOCARDIAL ISCHAEMIC INJURY
Abstract effectué
(1) UMR CNRS 7034, Compréhension de capsule, ILLKIRCH; (2) IGBMC, 1rue Laurent Friesl, ILLKIRCH;
Orale Mardi 15/04    7 O87 F Boutitie (1); F Gueyffier (2); JP Boissel (2); R Ecochard (1); METHODOLOGICAL ISSUES ON THE VALIDATION OF SYSTOLIC BLOOD PRESSURE AS A SURROGATE MARKER OF THE EFFECT OF ANTI-HYPERTENSIVE TREATMENTS ON THE REDUCTION OF THE RISK OF STROKE
Abstract effectué
(1) Faveur de Biostatistique, Maternités Civils de Lyon, LYON; (2) Faveur de pharmacologie dispensaire EA643, Séminaire Claude Bernard, LYON;
Orale Mardi 15/04    7 O88 V Leblais (1); F Pourageaud (1); R Marthan (2); B Muller (1); EVIDENCE FOR CONTRIBUTION OF ALPHA-ADRENOCEPTORS IN THE EFFECTS OF CGP12177 IN RAT PULMONARY ARTERIES
Abstract effectué
(1) Ouvroir de Pharmacologie – INSERM EMI 9937, Compréhension de Remède, BORDEAUX; (2) INSERM EMI 9937, Compréhension de Purge, BORDEAUX;
Orale Mardi 15/04    7 O89 V Richard (1); S Hurel (1); PY Litzler (2); E Scalbert (3); JP Bessou (2); C Thuillez (1); LACK OF FUNCTIONAL ROLE OF VASCULAR CHYMASE IN THE PRODUCTION OF ANGIOTENSIN II IN ISOLATED HAMSTER ARTERIES. COMPARISON WITH HUMAN VESSELS
Abstract effectué
(1) INSERM E9920, Compréhension de médicament, ROUEN; (2) Faveur de Opération Cardiaque, CHU, ROUEN; (3) IRIS, 6 Empressement des Pléiades, COURBEVOIE;
Orale Mardi 15/04    8 O90 C Fennec (1); BA Nic Dhonnchadha (1); M Hascoët (1); P Jolliet (1); M Bourin (1); IS DOPAMINE A LIMITING FACTOR IN ANTIDEPRESSANT-LIKE STUDIES IN THE FST?
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES;
Orale Mardi 15/04    8 O91 I Agrégat (1); R Bordet (1); A Al Khedr (2); D Deplanque (1); F Pasquier (2); C Libersa (3); COGNITIVE DECLINE WITH ALZHEIMER DISEASE (AD) AND FIBRATES : A BENEFIT ASSOCIATION ?
Abstract effectué
(1) EA 1046, Hosto Huriez CHRU Lille, LILLE; (2) EA 2691, Hosto Roger Salengro CHRU Lille, LILLE; (3) EA 1046, CIC INSERM 9301, Hosto Huriez, Hosto Cardiologique CHRU Lille, LILLE;
Orale Mardi 15/04    8 O92 D David (1); M Bourin (1); G Jego (2); C Przybylski (2); P Jolliet (1); AM Gardier (2); EFFECTS OF CHRONIC PAROXETINE AND CITALOPRAM TREATMENT BY DUAL IN VIVO APPROACHES: A INTRACEREBRAL MICRODIALYSIS AND A BEHAVIOURAL STUDIES IN AWAKE SWISS MICE
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES; (2) EA 3544 Lab. Neuropharmacologie, Compréhension de Remède Séminaire Paris-Sud, CHATENAY-MALABRY;
Orale Mardi 15/04    8 O93 V Beray-Berthat (1); N Croci (1); M Plotkine (1); I Margaill (1); ROLE OF POLYMORPHONUCLEAR NEUTROPHILS IN CEREBRAL ISCHEMIA-REPERFUSION IN RATS
Abstract effectué
(1) UPRES EA 2510 Ouvroir de Pharmacologie, Compréhension de Remède, Séminaire Paris V, PARIS;
Orale Mardi 15/04    8 O94 O Pétrault (1); M Forteresse (1); N Cotelle (2); M Laprais (1); J Vamecq (1); P Duriez (3); R Bordet (1); ANTIOXIDANTS-INDUCED PROTECTION OF CEREBRAL BLOOD VESSELS FUNCTION AFTER ISCHEMIA/REPERFUSION (I/R)
Abstract effectué
(1) Ouvroir de Pharmacologie, Compréhension de Purge de Lille 2, LILLE; (2) UPRESA 8009, Séminaire de Lille1, VILLENEUVE D’ASCQ; (3) INSERM U545, Université Pastoureau de Lille, LILLE;
Orale Mardi 15/04    8 O95 B Le Foll (1); J Diaz (2); G Villafane (3); P Cesaro (3); A Mimran (3); M Marques (3); G Lagrue (4); S Car-ferry (1); V Attentionné (1); P Sokoloff (1); NICOTINE ET RECEPTEUR D3 DE LA DOPAMINE : IMPLICATIONS DANS LA DEPENDANCE ET LA MALADIE DE PARKINSON
Abstract effectué
(1) INSERM U573, 2 ter rue d’Alésia, PARIS; (2) Ouvroir de Physiologie, Compréhension de Remède, PARIS; (3) Faveur de Neurologie, Hopital Henri Mondor, CRETEIL; (4) Faveur de Tabacologie, Hopital Albert Chenevier, CRETEIL;
Orale Mardi 15/04    8 O96 G Michel (1); L Gueyrard (2); M Bongrand (1); B Michel (2); EFFICACY OF ACETYLCHOLINESTERASE INHIBITORSIN LEWY BODIES DEMENTIA
Abstract effectué
(1) Remède, Hosto de la Élaboration, MARSEILLE; (2) Faveur de neurogeriatrie, Hosto Heureuse Merveille, MARSEILLE;
Orale Mardi 15/04    8 O97 B Guiard (1); S Seyler (1); A Gardier (1); SUSTAINED BLOCKADE OF NEUROKININ-1 RECEPTORS MODIFIES 5-HT1A AUTORECEPTOR ACTIVITY: AN IN VIVO INTRACEREBRAL MICRODIALYSIS STUDY IN MICE
Abstract effectué
(1) EA 3544 Lab. Neuropharmacologie, Compréhension de Remède Séminaire Paris-Sud, CHATENAY-MALABRY;
Orale Mardi 15/04    8 O98 P Gele (1); D Deplanque (1); I Six (1); S Nion (2); JC Fruchart (3); R Ceccheli (2); B Staels (3); P Duriez (3); R Bordet (1); PROPHYLACTIC PPAR-ALPHA ACTIVATION DECREASES BRAIN INJURY AFTER TRANSIENT ISCHEMIA IN MICE
Abstract effectué
(1) Ouvroir de Pharmacologie, Compréhension de Purge de Lille 2, LILLE; (2) Compréhension des Sciences Pantalon Perrin, Séminaire d’Artois, LENS; (3) INSERM U 545, Université Pastoureau de Lille, Fac. de Pharma. Lille2, LILLE;
Orale Mardi 15/04    8 O99 F Patricien (1); J Salzmann (1); J Wilson (1); M Mas Nieto (1); BP Roques (1); IMBALANCE IN ENDOGENOUS CCK/OPIOID SYSTEMS MAY BE INVOLVED IN VULNERABILITY TO DRUG DEPENDENCE
Abstract effectué
(1) INSERM U266, CNRS FRE 2463, Séminaire René Descartes, PARIS;
Orale Mardi 15/04    9 O100 JM Treluyer (1); G Bowers (2); N Cazaali (1); E Rey (1); M Sonnier (3); G Pons (1); T Cresteil (3); EVALUATION OF THE MATURATION OF HUMAN CYP ON THE OXIDATIVE METABOLISM OF AMPRENAVIR
Abstract effectué
(1) Pharmacologie, Hosto Cochin Heureux Vincent de Paul, PARIS; (2) GSK, GSK, NC, USA; (3) ICSN, CNRS, GIF SUR YVETTE;
Orale Mardi 15/04    9 O101 N Picard (1); T Cresteil (2); Y Le Meur (3); P Marquet (1); IDENTIFICATION OF A NEW PHASE I METABOLITE OF MYCOPHENOLIC ACID AND METABOLIC PATHWAY INVOLVED
Abstract effectué
(1) Faveur de Pharmacologie et Toxicologie, CHU, LIMOGES; (2) ICSN, CNRS UPR 2301, GIF-SUR-YVETTE; (3) Faveur de urologie, CHU, LIMOGES;
Orale Mardi 15/04    9 O102 R Serreau (1); M Fakhoury (1); Y Medard (1); AL Delezoide (2); M Peuchmaur (3); E Jacqz-Aigrain (1); EXPRESSION OF CYP3A AND PGP IN HUMAN PLACENTA : A PROSPECTIVE CONTROLLED STUDY
Abstract effectué
(1) Pharmacology Unit, Lolo Debré Hospital, PARIS; (2) Foetopathology unit, Lolo Debré Hospital, PARIS; (3) Anatomo-pathology Unit, Lolo Debré Hospital, PARIS;
Orale Mardi 15/04    9 O103 K Lacut (1); E Oger (1); M Alhenc-Gelas (2); V Kerlan (3); N Roudaut (3); M Encolure (4); M Aïach (5); PY Scarabin (2); D Mottier (1); DIFFERENTIAL EFFECTS OF ORAL AND TRANSDERMAL ESTROGEN/PROGESTERONE REGIMENS ON SENSITIVITY TO ACTIVATED PROTEIN C AMONG POSTMENOPAUSAL WOMEN: A RANDOMISED (S.A.R.A.H) TRIAL
Abstract effectué
(1) Préfecture de Purge Foyer et Phtisiologie, CHU Mulassière Livide, BREST; (2) Union INSERM 258, Hosto Paul Savane, VILLEJUIF; (3) Faveur d’Endocrinologie, CHU Mulassière Livide, BREST; (4) Faveur de Obstétrique, CHU Morvan, BREST; (5) Ouvroir d’Hématologie, Hosto Occidental Georges Pompidou, PARIS;
Orale Mardi 15/04    9 O104 C Moro (1); J Galitzky (1); C Sengenès (1); F Crampes (1); I De Glisezinski (1); C Thalamas (2); M Lafontan (1); M Berlan (1); EVIDENCE FOR A NON-ADRENERGIC LIPOLYSIS IN HUMAN SUBCUTANEOUS ADIPOSE TISSUE DURING EXERCISE: PUTATIVE ROLE OF NATRIURETIC PEPTIDES.
Abstract effectué
(1) INSERM U317, Compréhension de Purge, TOULOUSE; (2) CIC, CHU Purpan, TOULOUSE;
Orale Mardi 15/04    9 O105 C Delayre-Orthez (1); S Demesy (1); E Mathieu (1); N Frossard (1); F Pons (1); EXPOSURE TO ENDOTOXIN EXHIBITS DUAL AND DOSE-DEPENDENT EFFECTS ON ALLERGEN SENSITIZATION AND CHALLENGE IN A MOUSE MODEL OF ASTHMA
Abstract effectué
(1) INSERM U425, Compréhension de capsule, ILLKIRCH;
Orale Mardi 15/04    9 O106 C Aoûtat (1); YY Cui (1); E Naline (1); M Bardou (1); C Advenier (1); NOCICEPTIN INHIBITS AIRWAY MICROVASCULAR LEAKAGE INDUCED BY HCL INTRA-OESOPHAGEAL INSTILLATION
Abstract effectué
(1) UPRES EA220, UFR Biomédicale des Saints Pères, PARIS;
Orale Mardi 15/04    9 O107 M Bardou (1); YM Toubouti (2); D Benhaberou-Châtain (1); E Rhame (2); AN Barkun (1); HIGH DOSE INTRAVENOUS PROTON PUMP INHIBITION DECREASE BOTH RE-BLEEDING AND MORTALITY IN HIGH-RISK PATIENTS WITH ACUTE PEPTIC ULCER BLEEDING: A SERIES OF META-ANALYSES
Abstract effectué
(1) Gastroenterology Department, McGill University Health Center, MONTREAL, CANADA; (2) Clinical Epidemiology Unit, McGill University Health Center, MONTREAL, CANADA;
Orale Mardi 15/04    9 O108 S Gautier (1); O Petrault (1); D Deplanque (1); J Caron (1); R Bordet (1); ROLE OF THROMBUS LYSIS AND VASCULAR WALL IMPAIRMENT IN RTPA-INDUCED CEREBRAL HEMORRHAGE DURING STROKE
Abstract effectué
(1) Pharmacologie EA1046, Compréhension de Purge, LILLE;
Orale Mardi 15/04    9 O109 A Tabernero (1); R Andriantsitohaina (1); S Chasserot (2); CD Muller (1); JM Reimund (3); CYCLOOXYGENASE (COX)-2 (COX-2) EXPRESSION AND ROLE OF VASOCONSTRICTOR PROSTANOIDS IN SMALL MESENTERIC ARTERIES (SMA) FROM PATIENTS WITH CROHN’S DISEASE (CD)
Abstract effectué
(1) CNRS UMR 7034, Compréhension de capsule, ILLKIRCH; (2) CNRS UPR 2356, Strasbourg, STRASBOURG; (3) Hépato-Gastroentérologie & Auditoire Nourricière, Hospices Universitaires de Strasbourg, STRASBOURG;
Proclamation Lundi 14/04   P21 C Victorri-Guignette (1); D Oliveira (1); M Bourin (1); P Jolliet (1); RISK PERCEPTION AND PHARMACOVIGILANCE SELF MEDICATION : AN OPINION SURVEY DROWN ON CONSUMERS AND PHARMACISTS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES;
Proclamation Lundi 14/04   P22 M Bronnec (1); B Guitton (2); M Bourin (1); P Jolliet (1); METABOLIC DISTURBANCES ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Faveur de Psychiatrie Hospitalo-Étudiant, Hosto Heureux Jacques – CHU, NANTES;
Proclamation Lundi 14/04   P23 M Bronnec (1); E Lolarge (2); R Bocher (2); M Bourin (1); P Jolliet (1); CLOZAPINE-INDUCED NEUTROPHILIA : A RARE HEMATOLOGICAL SIDE-EFFECT
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Faveur de Psychiatrie V, Hosto Heureux Jacques – CHU, NANTES;
Proclamation Lundi 14/04   P24 A Chiffoleau (1); D Drui (2); G Veyrac (1); Y Cariou (1); JM Chavigny (3); B Milpied (4); M Bourin (1); P Jolliet (1); ALLERGY TO BETA BLOCKERS OR ALLERGY REVEALED BY BETA BLOCKERS ? CASE REPORT AND ITS ALLERGIC CROSS REACTION THERAPEUTIC MANAGEMENT
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Asile cardiologique et des maladies vasculaires, CHU, NANTES; (3) Foyer Curatif Sud Loire Mauvoisins, Rue Mauvoisins, NANTES; (4) Faveur de Dermatologie, CHU, NANTES;
Proclamation Lundi 14/04   P25 A Chiffoleau (1); T Ponge (2); G Veyrac (1); F Pajot (1); J Barrier (2); M Bourin (1); P Jolliet (1); HYDROXYCARBAMIDE (HYDREA®) AND GEANT NECROTIC ULCERATIONS IN AN OLD THROMBOCYTEMIC PATIENT
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Faveur de Purge Foyer, CHU, TOULOUSE;
Proclamation Lundi 14/04   P26 CH Ben Salem (1); J Michot (1); V Pras (1); S Makki (1); M Biour (1); DRUG-INDUCED ACUTE PANCREATITIS: AN UPDATED DATABASE
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Hosto Heureux-Antoine, PARIS;
Proclamation Lundi 14/04   P27 G Mounier (1); C Guy (1); MN Beyens (1); M Ratrema (1); M Ollagnier (1); FLURBIPROFEN-INDUCED ACUTE RENAL FAILURERESULTS OF THE FRENCH POST-MARKETING SURVEILLANCE
Abstract effectué
(1) Foyer de Pharmacovigilance, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE;
Proclamation Lundi 14/04   P28 G Durrieu (1); E Gorsse (1); J Montastruc (1); NEWSPAPERS : SOURCE OF INFORMATION ABOUT DOPING IN SPORTS
Abstract effectué
(1) Faveur de Pharmacologie Asile, Secours Méd de Combat Dopage, Compréhension de Purge, TOULOUSE;
Proclamation Lundi 14/04   P29 G Veyrac (1); F Briec (2); A Chiffoleau (1); H Villain (1); H Le Marec (2); M Bourin (1); P Jolliet (1); DILATED CARDIOMYOPATHY AFTER CHRONIC TREATMENT WITH TRICYCLIC ANTIDEPRESSANT DRUGS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Asile cardiologique et des maladies vasculaires, CHU, NANTES;
Proclamation Lundi 14/04   P30 G Veyrac (1); MT Legall (2); A Chiffoleau (1); M Bourin (1); P Jolliet (1); PROLONGED BLEEDING TIME BY PAROXETINE (DEROXAT®)
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Université de Histologie 9 embarcadère Moncousu, NANTES; (2) Chemin R.Rolland, Rézé, REZE;
Proclamation Lundi 14/04   P31 T Trenque (1); F Cardona (1); A Molia (1); H Millart (1); ML Utérin (1); INTRADISCAL CALCIFICATION WITH INTRADISCAL INJECTION OF GLUCOCORTICOIDS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Foyer Abordable Étudiant, REIMS;
Proclamation Lundi 14/04   P32 A Molia (1); A Delcourt (2); MA Preiss (2); ML Utérin (1); T Trenque (1); EPOETIN : A DOSE-DEPENDENT MARKED THROMBOCYTOSIS ?
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Foyer Abordable Étudiant, REIMS; (2) Faveur de Cardiologie, Foyer Abordable, SAINT-DIZIER;
Proclamation Lundi 14/04   P33 F Cardona (1); G Jolimoy (2); C Kreft-Jaïs (2); T Trenque (1); IMPROVING REPORTING OF ADVERSE EVENTS RELATED TO ANTICANCER DRUGS TREATMENT
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Foyer Abordable Étudiant, REIMS; (2) Union de Pharmacovigilance, AFSSAPS, SAINT DENIS;
Proclamation Lundi 14/04   P34 AP Jonville-Bera (1); F Tauveron (1); L Bensouda (1); F Artistique-Salinas (1); E Autret-Leca (1); EXTRAPYRAMIDAL REACTIONS FROM CURRENT SSRI AND NEUROLEPTIC USE
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, CHRU, TOURS;
Proclamation Lundi 14/04   P35 M Ollagnier (1); P Caton (2); B Trombert (3); C Guy (1); P Beck (2); GASTROINTESTINAL HAEMORRHAGES AND NSAIDS : A PROSPECTIVE STUDY
Abstract effectué
(1) Foyer de Pharmacovigilance, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (2) URCAM-CPAM de St-Etienne, 3 Chemin du Directeur Emile Loubet, SAINT-ETIENNE; (3) Faveur de Esprit Certifiée (S.S.P.I.M.), Hosto de Heureux-Pantalon-Bonnefonds, SAINT-JEAN-BONNEFONDS;
Proclamation Lundi 14/04   P36 I Heran (1); MP Paillette (1); H Peyriere (1); D Hillaire-Buys (1); JP Blayac (1); TWO CASES OF GYNECOMASTIA IN CHILDREN TREATED WITH CETIRIZINE, A SECOND GENERATION ANTIHISTAMINE
Abstract effectué
(1) Faveur de Pharmacologie Médicale et Toxicologie, Hosto Lapeyronie, MONTPELLIER;
Proclamation Lundi 14/04   P37 J Micallef (1); S Tardieu (1); K Khalech (1); O Blin (1); BENZODIAZEPINE AND HICCUPS : THREE CASE REPORTS
Abstract effectué
(1) CPCET & Faveur de Pharmacologie Asile, CHU Timone, MARSEILLE;
Proclamation Lundi 14/04   P38 O Maillard (1); C Guy (1); M Burellier (2); MN Beyens (1); M Ratrema (1); G Mounier (1); D Michel (3); M Ollagnier (1); REVERSIBLE DEMENTIA ASSOCIATED WITH VALPROIC ACID MONOTHERAPY
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (2) 11 Chemin de la glèbe, , CRAPONNE SUR ARZON; (3) Faveur de Neurologie, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE;
Proclamation Lundi 14/04   P39 V Pinzani (1); D Hillaire-Buys (1); S Petit (2); H Peyrière (1); N Mirfendereski (1); JP Blayac (1); ETONOGESTREL AND HEMORRHAGIC STROKE: A CASE REPORT
Abstract effectué
(1) Faveur de Pharmacologie Médicale et Toxicologie, Hosto Lapeyronie, MONTPELLIER; (2) Préfecture de Purge Concret et Rétablissement, Hosto Caremeau, NIMES;
Proclamation Lundi 14/04   P40 C Cabou (1); H Bagheri (1); A Cantagrel (2); B Mazière (2); JL Montastruc (1); RETROSPECTIVE ANALYSIS OF ADVERSE REACTIONS OF INFLIXIMAB IN A DEPARTMENT OF RHUMATOLOGY
Abstract effectué
(1) Faveur de Pharmacologie Asile, Compréhension de Purge-CHU, TOULOUSE; (2) Faveur de Rhumatologie, CHU Rangueil, TOULOUSE;
Proclamation Lundi 14/04   P41 ML Hemery (1); V Pinzani (1); P Quittet (2); V Faucherre (3); C Janbon (4); JP Blayac (1); THROMBOEMBOLIC COMPLICATIONS AND INTERFERON ALFA 2B THERAPY
Abstract effectué
(1) Pharmacologie Médicale et Toxicologie, Hosto Lapeyronie, MONTPELLIER; (2) Hématologie, Hosto Lapeyronie, MONTPELLIER; (3) Purge F, Hosto Heureux-Eloi, MONTPELLIER; (4) Purge B, Hosto Heureux-Eloi, MONTPELLIER;
Proclamation Lundi 14/04   P42 P Lochet (1); V Faucherre (2); V Pinzani (1); ML Hemery (1); D Hillaire Buys (1); JP Blayac (1); REVERSIBLE INSULIN-DEPENDENT DIABETES MELLITUS ASSOCIATED WITH INTERFERON THERAPY IN A CHRONIC HEPATITIS C PATIENT
Abstract effectué
(1) Pharmacologie Médicale et Toxicologie, Hosto Lapeyronie, MONTPELLIER; (2) Purge Foyer F, Hosto Heureux Eloi, MONTPELLIER;
Proclamation Lundi 14/04   P43 N Mirfendereski (1); P Lochet (1); A Gauthey-abderrahim (1); V Pinzani (1); D Hillaire-Buys (1); JP Blayac (1); LAUROMACROGOL AND TRANSIENT NEUROLOGIC DISORDERS
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Lapeyronie, MONTPELLIER;
Proclamation Lundi 14/04   P44 ML Laroche (1); F Macian-Montoro (2); L De Lumley (3); M Amaniou (1); M Lacoste (2); L Montagnard (1); CEREBRAL ISCHEMIA AND ISOTRETINOIN : TWO CASE REPORTS
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, CHU Dupuytren, LIMOGES; (2) Faveur de Neurologie, CHU Dupuytren, LIMOGES; (3) Préfecture de Pédiatrie Médicale, CHU Dupuytren, LIMOGES;
Proclamation Lundi 14/04   P45 C Lafay (1); C Chausseur (1); C Remblier (1); MC Perault (1); NON CONFORMITY IN PHARMACOVIGILANCE
Abstract effectué
(1) Faveur de Pharmacologie Asile-CRPV, CHU, POITIERS;
Proclamation Lundi 14/04   P46 D Raylet (1); C Lafay (1); S Favreliere (1); B Dreyfus (2); MC Perault (1); RABEPRAZOLE INDUCED ERYTHEMA NODOSUM
Abstract effectué
(1) Faveur de Pharmacologie Asile-CRPV, CHU, POITIERS; (2) Faveur d’Hématologie de Lunette, CHU, POITIERS;
Proclamation Lundi 14/04   P47 L Chauvelot-Moachon (1); M De Menton (2); S Abad (2); C Vauzelle (1); F Bavoux (1); P Livide (2); TRAMADOL, WITH THE ANTIDEPRESSANTS INHIBITORS OF SEROTONIN REUPTAKE, INDUCE A SEROTONIN SYNDROME
Abstract effectué
(1) Pharmacovigilance, Compréhension de Purge et Hosto Cochin, PARIS; (2) Purge Foyer, Hosto Cochin, PARIS;
Proclamation Lundi 14/04   P48 C Remblier (1); G Desprairies (2); C Lafay (1); MC Perault (1); ORIGINAL ANGIOGRAPHIC PATTERN AND EDEMA RELATED TO METHYSERGIDE
Abstract effectué
(1) CRPV-Faveur de Pharmacologie Asile, CHU, POITIERS; (2) Purge-Phlébologie, Fraternel, LA ROCHELLE;
Proclamation Lundi 14/04   P49 V Lipide-Champel (1); H Masson (1); C Lematte (1); P Pakula (1); B Roussel (2); K Masmoudi (1); M Andréjak (1); ASSESSMENT OF ORAL ANTICOAGULATION MANAGEMENT QUALITY AMONG PATIENTS ADMITTED TO THE AMIENS UNIVERSITY HOSPITAL
Abstract effectué
(1) Pharmacovigilance Foyer, CHU Amiens Sud, AMIENS; (2) Haematology laboratory, CHU Amiens Polaire, AMIENS;
Proclamation Lundi 14/04   P50 C Remblier (1); C Pradère (2); S Favrelière (1); MC Perault (1); POSSIBLE SEROTONIN SYNDROME ASSOCIATED WITH FLUOXETINE AND HYDROMORPHONE COADMINISTRATION
Abstract effectué
(1) CRPV-Faveur de Pharmacologie Asile, CHU, POITIERS; (2) Médicament de Consécution D, CHU, POITIERS;
Proclamation Lundi 14/04   P51 AC Resende (1); S Faure (1); S Nadaud (2); I Lartaud-Idjouadiène (1); J Atkinson (1); C Capdeville-Atkinson (1); MELATONIN ATTENUATES THE DECREASE IN NORADRENALINE (NA)-INDUCED CONTRACTION OF RAT AORTIC RINGS PRODUCED BY PROLONGED INCUBATION
Abstract effectué
(1) EA 3448, Compréhension de Remède, NANCY; (2) INSERM 525, 91 bd de l’Hosto, PARIS;
Proclamation Lundi 14/04   P52 A Rupin (1); J R Paysant (1); T J Verbeuren (1); ANOXIA/REOXYGENATION AND AN INFLAMMATORY CONTEXT SYNERGISTICALLY INCREASE E-SELECTIN EXPRESSION THROUGH NADPH OXIDASE IN HUVECS
Abstract effectué
(1) Bouchée Phlébologie, Université de Mièvrerie Servier, SURESNES;
Proclamation Lundi 14/04   P53 K Chalupsky (1); I Lobysheva (2); G Entlicher (3); F Nepveu (2); JC Stoclet (1); B Muller (4); N-HYDROXYLATED COMPOUNDS AS SUBSTRATES FOR NO PRODUCTION IN BLOOD VESSELS
Abstract effectué
(1) Pharmacologie et Physicochimie, CNRS UMR 7034, Compréhension de Remède, Séminaire Paillette Pastoureau, ILLKIRCH; (2) Pharmacophores Redox Phytochimie & Radiobiologie, EA-3030, Compréhension de Remède, Séminaire Paul Sabatier, TOULOUSE; (3) Departement of Biochemistry, Charles University, PRAGUE, TCHEQUIE; (4) Pharmacologie INSERM EMI 9937, Compréhension de Remède, Séminaire Victor Segalen, BORDEAUX;
Proclamation Lundi 14/04   P54 P Guerard (1); O Barthez (1); F Goirand (2); L Rochette (1); JP Dumas (1); M Dumas (1); M Bardou (1); THE HMG-COA REDUCTASE INHIBITOR, PRAVASTATIN, PREVENTS THE DEVELOPMENT OF MONOCROTALINE-INDUCED PULMONARY HYPERTENSION IN THE RAT
Abstract effectué
(1) LPPCE, Compréhension de médicament, DIJON; (2) Ouvroir de Physiologie, Compréhension de capsule, CHATENAY-MALABRY;
Proclamation Lundi 14/04   P55 J Paysant (1); A Rupin (1); P Sansilvestri-Morel (1); N Lembrez (1); T Verbeuren (1); ANOXIA/REOXYGENATION INDUCED A NADPH OXIDASE DEPENDENT OXIDATIVE STRESS IN ENDOTHELIAL CELLS WHICH OVEREXPRESSED E-SELECTIN VIA NFKB ACTIVATION
Abstract effectué
(1) Bouchée Phlébologie, Université de Mièvrerie Servier, SURESNES;
Proclamation Lundi 14/04   P56 S Simonet (1); C Badier Implorer (1); J R Paysant (1); C Vayssettes Courchay (1); A Rupin (1); Y Menant (1); C Hennape (1); G Gautier (1); T J Verbeuren (1); EFFECTS OF NADH AND NADPH IN RABBIT AORTA : SIGNALLING PATHWAY AND COMPARISON WITH EFFECTS NOTED IN RABBIT SAPHENOUS VEIN
Abstract effectué
(1) Bouchée Phlébologie, Université de Mièvrerie Servier, SURESNES;
Proclamation Lundi 14/04   P57 F Pourageaud (1); V Leblais (1); R Marthan (2); B Muller (1); PHENOXYBENZAMINE PRE-TREATMENT REVEALS AN ATYPICAL BETA-ADRENERGIC RELAXATION IN RAT INTRAPULMONARY ARTERIES
Abstract effectué
(1) Ouvroir Pharmacologie, INSERM EMI9937, Compréhension de Remède, BORDEAUX; (2) Ouvroir de Physiologie, INSERM EMI9937, Compréhension de Purge, BORDEAUX;
Proclamation Lundi 14/04   P58 N Ryckelynck (1); C Laurent (1); R Morello (2); B Mosquet (1); J Lacotte (1); E Singlas (3); A Coquerel (1); OBSERVATIONAL STUDY ABOUT GENERIC DRUGS USE IN BASSE NORMANDIE (ACHIEVED DURING 2001) AMONG FIVE HUNDRED GENERAL PRACTITIONERS
Abstract effectué
(1) Pharmacovigilance, CHU, CAEN; (2) Infographie Medicale, CHU, CAEN; (3) Chimie Médicinal, Compréhension de Remède, Séminaire de Caen, CAEN;
Proclamation Lundi 14/04   P59 A Umar (1); F Depont (1); A Trictrac (1); S Lignot (1); B Bégaud (1); MC Segur (2); M Boisseau (3); N Moore (1); EFFECTS OF ARMAGNAC OR VODKA ON PLATELET AGGREGATION IN HEALTHY VOLUNTEERS: A RANDOMIZED CLINICAL TRIAL
Abstract effectué
(1) Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) BNIA, EAUZE; (3) Hématologie, CHU Pourpre, BORDEAUX;
Proclamation Lundi 14/04   P60 M Billing-Grima (1); J Anjuere (1); J Steger (1); C Bourdenet-Coquard (1); JL Imbs (2); RELATION BETWEEN PLASMA ANGIOTENSIN II AND TISSUE INTERNALIZATION VIA THE AT1 RECEPTOR
Abstract effectué
(1) Université de Pharmacologie, Compréhension de Purge Séminaire Paillette Pastoureau, STRASBOURG; (2) Faveur de Maladies Vasculaires, Hypertesion et Pharmacologie dispensaire, Hospices Universitaires de Strasbourg, STRASBOURG;
Proclamation Lundi 14/04   P61 M Barthelmebs (1); N Wiernsperger (2); JR Rapin (3); M Grima (4); JL Imbs (4); METFORMIN ACCUMULATION IN THE KIDNEY OF DIABETIC RATS DOES NOT ALTER RENAL FUNCTION NOR WORSEN IT DURING ACUTE RENAL FAILURE
Abstract effectué
(1) INSERM E0015, Compréhension de Purge, STRASBOURG; (2) Merck-Lipha, 37 rue Heureux-Latin, LYON; (3) Dospharma, 3 rue du Tronquet, MONT SAINT AIGNAN; (4) Université de Pharmacologie, Compréhension de Purge, STRASBOURG;
Proclamation Lundi 14/04   P62 M Diebolt (1); L Utérin (2); F Auger (2); R Andriantsitohaina (1); HUMAN TISSUE-ENGINEERED VASCULAR MEDIA AS A PHARMACOLOGICAL TOOL TO STUDY THE REGULATION OF CONTRACTION BY POLYPHENOLS
Abstract effectué
(1) UMR CNRS 7034, Compréhension de capsule, ILLKIRCH; (2) Ouvroir d’organogénèse rationaliste, Séminaire de Laval, QUEBEC, CANADA;
Proclamation Lundi 14/04   P63 L Guedon-Moreau (1); JL Gayet (2); Y Frances (3); M Galinier (4); H Lardoux (5); C Libersa (1); INCIDENCE OF ADVERSE EVENTS AFTER ELECTRICAL CARDIOVERSION FOR ATRIAL FIBRILLATION IN EPCAF STUDY
Abstract effectué
(1) Pharmacologie, CHRU LILLE, LILLE; (2) -, COLOMBES; (3) Cardiologie, Hosto Polaire, MARSEILLE; (4) Cardiologie, CHU Rangueil, TOULOUSE; (5) Cardiologie, Rassemblé Abordable Sud Francilien, CORBEIL ESSONNES;
Proclamation Lundi 14/04   P64 S Davani (1); A Marandin (2); N Mersin (3); B Royer (1); H Reyssie (1); B Kantelip (4); JP Kantelip (1); MESENCHYMAL PROGENITOR CELLS DIFFERENTIATE TO AN ENDOTHELIAL PHENOTYPE, ENHANCE VASCULAR DENSITY AND IMPROVE HEART FUNCTION IN A RAT CELLULAR CARDIOMYOPLASTY MODEL
Abstract effectué
(1) Pharmacologie-EA479, CHU Pantalon Minjoz, BESANÇON; (2) EFS-EA2284, Etablissement Gaulois du Généalogie, BESANÇON; (3) Opération Cardiovasculaire et Thoracique-EA479, CHU Pantalon Minjoz, BESANÇON; (4) Anatomopathologie-EA479, CHU Pantalon Minjoz, BESANÇON;
Proclamation Lundi 14/04   P65 JS Hulot (1); JL Démolis (1); R Ravine (1); S Strabach (1); S Christin-Maitre (2); C Funck-Brentano (1); ABSENCE OF INFLUENCE OF ENDOGENOUS ESTROGENS ON QT INTERVAL DURATION
Abstract effectué
(1) Foyer d’enquête dispensaire, Hosto Heureux-Antoine, PARIS; (2) Faveur d’Endocrinologie, Hosto Heureux-Antoine, PARIS;
Proclamation Lundi 14/04   P66 A Umar (1); M Boisseau (2); MC Segur (3); N Moore (1); EFFECT OF AGE OF ARMAGNAC EXTRACT AND DURATION OF TREATMENT ON ANTITHROMBOTIC EFFECTS IN A RAT THROMBOSIS MODEL
Abstract effectué
(1) Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) Hématologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (3) BNIA, EAUZE;
Proclamation Lundi 14/04   P67 P Philip-Couderc (1); A Pathak (1); F Smih (1); JM Senard (1); X Encolure (2); F Strophe (2); M Galinier (1); P Verwaerde (1); J Roncalli (1); T Castillo (1); P Rouet (1); HIGH FAT DIET INDUCES SYNTHESIS OF A NEW CARDIAC SECRETED PROTEIN THAT IS DETECTED IN HDL3
Abstract effectué
(1) INSERM U317, Compréhension de Purge, Faveur de Pharmacologie, TOULOUSE; (2) INSERM U563, CHU Purpan, TOULOUSE;
Proclamation Lundi 14/04   P68 P Philip-Couderc (1); F Smih (1); A Pathak (1); JM Senard (1); M Galinier (1); P Vervaerde (1); J Roncalli (1); P Massabuau (1); T Castillo (1); P Rouet (1); A NEW CARDIAC HOMEOPROTEIN INDUCED BY NUTRITIONAL OBESITY
Abstract effectué
(1) INSERM U317, Compréhension de Purge, Faveur de Pharmacologie, TOULOUSE;
Proclamation Lundi 14/04   P69 C Arnaud (1); M Spirituel-Faure (1); D Godin-Ribuot (1); JL Cracowski (1); C Ribuot (1); HEAT STRESS TRIGGERS PROTEIN KINASE C EPSILON TRANSLOCATION AND HSP27 PHOSPHORYLATION
Abstract effectué
(1) Ouvroir Anoxie Physio-Pathologie, Compréhension de Remède, GRENOBLE;
Proclamation Lundi 14/04   P70 C Barel (1); M Belkhiria (2); B Bui-Xuan (3); J Descotes (1); PH Aristocrate (4); MC Gagnieu (5); F Arnal (1); P Tsibiribi (1); Q Timour (1); HEMODYNAMIC AND CARDIAC ELECTROPHYSIOLOGICAL EFFECTS OF ROPIVACAINE COMBINED WITH VARIOUS ANTIARRHYTHMIC DRUGS IN THE PIG
Abstract effectué
(1) Ouvroir de Pharmacologie Médicale, Séminaire Claude Bernard, LYON; (2) Ouvroir de Pharmacologie, Séminaire de Monastir, MONASTIR, TUNISIE; (3) Préfecture d’Antalgie Ranimation, Hosto Edouard Herriot, LYON; (4) Faveur de Cardiologie, Hosto Paillette Pradel, BRON; (5) Ouvroir de Biochimie, Hosto Edouard Herriot, LYON;
Proclamation Lundi 14/04   P71 N Ripoll (1); DJ David (1); MC Colombel (1); M Hascoët (1); M Bourin (1); ANTIDEPRESSANT-LIKE EFFECTS IN VARIOUS MICE STRAINS IN THE TAIL SUSPENSION TEST
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES;
Proclamation Lundi 14/04   P72 JM Reymann (1); G Bantsiele (1); M Bourin (2); EFFECT OF MILNACIPRAN COMPARED TO REFERENCE COMPOUNDS ON POST-STROKE EMOTIONAL DISTURBANCES, ASSESSED IN ANIMAL MODELS OF DEPRESSION OR ANXIETY
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Faveur de Pharmacologie Asile et Expérimentale, RENNES; (2) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES;
Proclamation Lundi 14/04   P73 BA Nic Dhonnchadha (1); M Hascoët (1); P Jolliet (1); M Bourin (1); ANXIOLYTIC-LIKE PROPERTIES OF DOI: EVIDENCE FOR A 5-HT2A RECEPTOR MODE OF ACTION
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES;
Proclamation Lundi 14/04   P74 M Boulouard (1); V Mauduit (1); V Lelong (1); D Debruyne (2); A Coquerel (2); INTERACTION BETWEEN BUPRENORPHINE AND CLORAZEPATE DIPOTASSIC ON SPONTANEOUS ACTIVITY AND ANXIETY IN THE MOUSE
Abstract effectué
(1) Ouvroir de pharmacologie CERMN UPRES EA 2126, Compréhension de Remède, Séminaire de Caen, CAEN; (2) Faveur de Pharmacologie et CEIP Polaire Couchant, CHU, CAEN;
Proclamation Lundi 14/04   P76 V Bertaina-Anglade (1); E Enjuanes (1); C Drieu La Mezzanine (1); EFFECTS OF THIOPERAMIDE, AN HISTAMINE H3 ANTAGONIST ON MEMORY PERFORMANCE IN AN OBJECT RECOGNITION TASK IN C57BL6/J MICE
Abstract effectué
(1) BIOTRIAL, Department of Preclinical Pharmacology, RENNES;
Proclamation Lundi 14/04   P77 C Courteix (1); AM Privat (1); T Pélissier (2); A Eschalier (3); J Fialip (1); SPINAL EFFECT OF AGMATINE ON HYPERALGESIA, ALLODYNIA AND MORPHINE-INDUCED ANALGESIA IN DIABETIC RATS
Abstract effectué
(1) INSERM 9904 Ouvroir de Pharmacologie Médicale, Compréhension de Remède, CLERMONT-FD; (2) Department of pharmacology, Faculty of Medicine University of Chile, SANTIAGO, CHILI; (3) INSERM 9904 Ouvroir de Pharmacologie Médicale, Compréhension de Purge, CLERMONT-FD;
Proclamation Lundi 14/04   P78 Y Pelloux (1); J Costentin (1); D Duterte-Barrer (1); NOVELTY SEEKING ON THE PLAYGROUND MAZE PREDICTS DRUG CONSUMPTION IN RATS
Abstract effectué
(1) UMR CNRS 6036, IFRMP 23, Compréhension de Purge et de Remède, ROUEN;
Proclamation Lundi 14/04   P79 F Loiseau (1); C Le Bihan (1); M Hamon (1); MH Thiébot (1); LACK OF EFFECTS OF MELATONIN IN TWO ANXIOGENIC CONFLICT PROCEDURES IN RATS
Abstract effectué
(1) INSERM U288, Compréhension de Purge Compassion-Salpêtrière, PARIS;
Proclamation Mardi 15/04   10  P110 MJ Pantalon-Pastor (1); F Rodor (1); N Nguyen (1); N Prost (1); M Boyer (1); B Gueniot (1); A Paklesa (1); M Valli (1); CALCIUM CHANNEL BLOCKERS AND PHOTOSENSITIVITY
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, 249, Bd de Heureuse-Merveille, MARSEILLE;
Proclamation Mardi 15/04   10  P111 E Polard (1); P Latour (2); A Biraben (3); D Bentue-Attraper (4); O Cens (4); H Allain (4); DRUG INDUCED ENCEPHALOPATHY IN SIX EPILEPTIC PATIENTS: TOPIRAMATE ? VALPROATE ? OR BOTH ?
Abstract effectué
(1) Foyer de Pharmacovigilance, Hosto Pontchaillou, RENNES; (2) Faveur de Neurologie, Hosto Mulassière Livide, BREST; (3) Faveur de Neurologie (Union Epilepsie), Hosto Pontchaillou, RENNES; (4) Ouvroir de Pharmacologie Expérimentale et Asile, Compréhension de Purge, RENNES;
Proclamation Mardi 15/04   10  P112 E Polard (1); J Boulliat (2); F Merlu (1); D Bentue-Attraper (3); O Cens (3); H Allain (3); MYOCLONIC ENCEPHALOPATHY: A DELETERIOUS INTERACTION BETWEEN LEVODOPA AND PROTON PUMP INHIBITORS
Abstract effectué
(1) Foyer de Pharmacovigilance, Hosto Pontchaillou, RENNES; (2) Faveur de Neurologie, Foyer Abordable Cité en Bresse, BOURG EN BRESSE; (3) Ouvroir de Pharmacologie Expérimentale et Asile, Compréhension de Purge, RENNES;
Proclamation Mardi 15/04   10  P113 B Lewden (1); T Vial (1); E Elefant (2); A Nelva (3); P Carlier (4); J Descotes (1); Afcrpv (5); LOW-DOSE METHOTREXATE AND PREGNANCY: A FRENCH PROSPECTIVE COLLABORATIVE STUDY
Abstract effectué
(1) Foyer de Pharmacovigilance, Hosto Edouard Herriot, LYON; (2) Foyer de Renseignements sur les Agents Tératogènes, CHU Heureux-Antoine, PARIS; (3) Université Occidental des Génomutations, Rue Edmond Locard, LYON; (4) Foyer de Pharmacovigilance, Hosto Fernand Widal, PARIS; (5) Union Française des Noyaux Régionaux de Pharmacovigilance, Hosto St Charles, MONTPELLIER;
Proclamation Mardi 15/04   10  P114 MA Bénéfice (1); C Régiment (2); H Bagheri (1); A Lequellec (3); F Rolland (2); JL Montastruc (1); ADVERSE EFFECTS COULD UPSET THE TREATMENT OF ALCOHOL DEPENDENCE
Abstract effectué
(1) Faveur de Pharmacologie Asile, Compréhension de Purge-CHU, TOULOUSE; (2) Faveur d’Alccologie, Hospices de Lannemezan, LANNEMEZAN; (3) Faveur Remède, Hospices de Lannemezan, LANNEMEZAN;
Proclamation Mardi 15/04   10  P115 N Bernard (1); T Vial (1); G Bauguil (2); G Chamba (2); J Descotes (1); ADVERSE EFFECTS REPORTED BY COMMUNITY PHARMACY STUDENTS: A 6-MONTH STUDY
Abstract effectué
(1) Foyer de Pharmacovigilance, Hosto Edouard Herriot, LYON; (2) Compréhension de capsule, Préfecture de Pharmacologie, LYON;
Proclamation Mardi 15/04   10  P116 V Lipide-Champel (1); H Masson (1); B Roussel (2); JM Geslin (1); K Masmoud (1); M Andréjak (1); HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) : A PROPOS OF 64 OBSERVATIONS NOTIFIED TO AMIENS PHARMACOVIGILANCE CENTRE (CRPV)
Abstract effectué
(1) Pharmacovigilance Foyer, CHU Amiens Sud, AMIENS; (2) Haematology laboratory, CHU Amiens Polaire, AMIENS;
Proclamation Mardi 15/04   10  P117 M Masson (1); R Lagnaoui (1); G Miremont-Salamé (1); C Roussillon (1); E Apretna (1); A Laribière (1); F Haramburu (1); DIRECT-TO-PATIENTS INFORMATION FOR DRUGS: ONE-YEAR OBSERVATIONAL STUDY
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Préfecture de Pharmacologie, CHU, Séminaire Victor Segalen, BORDEAUX;
Proclamation Mardi 15/04   10  P118 S Kalimouttou (1); T Lobbedez (2); A Coquerel (1); J Lacotte (1); B Mosquet (1); B Hurault De Ligny (1); APHTOSIS : STUDY IN 28 RENAL TRANSPLANT RECIPIENTS TREATED BY SIROLIMUS
Abstract effectué
(1) Pharmacovigilance, CHU, CAEN; (2) Urologie, CHU, CAEN;
Proclamation Mardi 15/04   10  P119 S El Aïdli (1); I Rejeïbi (1); R Daghfous (1); S Trabelsi (1); MH Loueslati (1); M Lakhal (1); C Belkahia (1); SMELL DISORDERS INDUCED BY PYRAZINAMIDE
Abstract effectué
(1) Faveur de barème et d’exposé des conditions, Foyer Habitant de Pharmacovigilance, TUNIS, TUNISIE;
Proclamation Mardi 15/04   10  P120 S El Aïdli (1); I Rejeïbi (1); R Daghfous (1); S Trabelsi (1); MH Loueslati (1); M Lakhal (1); C Belkahia (1); ERYTHEMA MULTIFORME INDUCED BY ETHAMBUTOL
Abstract effectué
(1) Faveur de barème et d’exposé des conditions, Foyer Habitant de Pharmacovigilance, TUNIS, TUNISIE;
Proclamation Mardi 15/04   10  P121 F Bavoux (1); M Thierry (1); C Vauzelle -Gardier (1); L Chauvelot Moachon (1); POLYTHERAPY WITH HIGH DOSE OF PSYCHOTROPIC DRUGS DURING PREGNANCY,FETAL AND NEONATAL RISKS
Abstract effectué
(1) Union de Pharmacovigilance, Pharmacologie Faculte de Purge Cochin, PARIS;
Proclamation Mardi 15/04   10  P122 S El Aïdli (1); K Khiari (2); R Daghfous (1); S Trabelsi (1); T Ben Abdallah (2); MH Loueslati (1); M Ben Maïz (2); C Belkahia (1); A CASE OF SEVER LOCAL CUTANEOUS REACTIONS TO INSULIN : HUMAN INSULIN DESENSITIZATION RESULT
Abstract effectué
(1) Faveur de barème et d’exposé des conditions, Foyer Habitant de Pharmacovigilance, TUNIS, TUNISIE; (2) Faveur de Purge Foyer, Hosto Charles Nicolle, TUNIS, TUNISIE;
Proclamation Mardi 15/04   10  P123 C Bousquet (1); A Lillo-Le Louët (1); C Le Beller (1); G Lagier (2); PRINCIPLES OF SEMANTIC NETWORKS FOR AUTOMATED SIGNAL DETECTION IN PHARMACOVIGILANCE
Abstract effectué
(1) CRPV d’HEGP, Hosto Occidental Georges Pompidou, PARIS; (2) CRPV Fernand Widal, Hosto Fernand Widal, PARIS;
Proclamation Mardi 15/04   10  P124 L Lagarce (1); JM Thoulon (2); H Plauchu (3); P Lainé-Cessac (1); E Lolo (4); CALCIUM CHANNEL BLOCKERS IN PREGNANCY, THE EXPERIENCE OF THE FRENCH PHARMACOVIGILANCE CENTRES
Abstract effectué
(1) CRPV, Ouvroir de pharmacologie CHU, ANGERS; (2) Obstétrique gynécologie, hopital Edouard Herriot terrasse K, LYON; (3) Successible, Arrêt-Logos, LYON; (4) IEG, Université Occidental des génomutations, LYON;
Proclamation Mardi 15/04   10  P125 K Martin (1); S Lawson-Ayayi (2); G Miremont-Salamé (1); AM Formaggio (3); D Lacoste (3); M Dupon (3); T Schaverberke (4); P Mercié (3); JM Ragnaud (3); F Haramburu (1); F Dabis (2); SYMPTOMATIC OSTEOPENIA AND OSTEOPOROSIS IN HIV-INFECTED PATIENTS, AQUITAINE COHORT 1999 – 2002
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Préfecture de Pharmacologie, Séminaire Victor Segalen, CHU, BORDEAUX; (2) INSERM U330, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (3) Foyer d’Nouvelle et de Médicament sur l’Immunodéficience Bonne, CHU, BORDEAUX; (4) Faveur de Rhumatologie, CHU, BORDEAUX;
Proclamation Mardi 15/04   10  P126 F Bentaberry (1); K Martin (2); C Dumoulin (1); J Dehais (1); F Haramburu (2); F Liefferman (3); T Schaeverbeke (1); PERIPHERAL NEUROPATHY DURING LEFLUNOMIDE TREATMENT: A REPORT OF 5 CASES
Abstract effectué
(1) Faveur de Rhumatologie, CHU, BORDEAUX; (2) Foyer Siège de Pharmacovigilance, Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, CHU, BORDEAUX; (3) Faveur de Purge Foyer, CH, DAX;
Proclamation Mardi 15/04   10  P127 S Ginisty (1); N Granuleux (2); P Eftekhari (1); M Rajad (1); G Lagier (1); DEPRESSION IN HIV-POSITIVE PATIENTS TREATED WITH EFAVIRENZ : 87 CASES RECORDED IN FRENCH PHARMACOVIGILANCE DATABASE (FROM 13/09/1999 TO 31/01/2002)
Abstract effectué
(1) Foyer Siège de Pharmacovigilance, Hosto Fernand Widal, PARIS; (2) Affaire française de assurance hygiénique des produits de sensualité, Bld Anatole France, ST DENIS;
Proclamation Mardi 15/04   10  P128 L Laforest (1); R Harf (2); F Clouet (3); C Ségala (4); D Poizeau (4); G Pietri (1); Y Pacheco (2); E Van Cordon (1); RELATIONSHIP BETWEEN RAGWEED POLLINATION COUNTS AND DELIVERY OF ANTI ALLERGIC MEDICATION
Abstract effectué
(1) Union de Pharmacoépidémiologie, Foyer Abordable Étudiant Lyon Sud, PIERRE-BENITE; (2) Faveur de phtisiologie, Foyer Abordable Étudiant Lyon Sud, PIERRE-BENITE; (3) Faveur Curatif, Bagage Naïve d’Preuve Crise de Lyon, LYON; (4) SEPIA Esprit, MELRAND;
Proclamation Mardi 15/04   10  P129 F Depont (1); A Abouelfath (1); E Hunsche (2); I Addra (1); T Diatta (1); A Grelaud (1); N Moore (1); THERAPEUTIC MANAGEMENT OF CHRONIC LOW BACK PAIN IN FRANCE
Abstract effectué
(1) Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) Merck & Co., Whitehouse Terminus, NJ, USA;
Proclamation Mardi 15/04   10  P130 I Lacroix (1); S Saivin (2); M Lapeyre-Mestre (1); JL Montastruc (1); C Damase-Michel (1); EFFECTS OF MATERNAL PSYCHOTROPIC USE OR ABUSE IN NEWBORNS : PRELIMINARY RESULTS OF THE PHARMACOEPIDEMIOLOGIC STUDY NENUPHAR
Abstract effectué
(1) Faveur de Pharmacologie Asile, Compréhension de Purge, TOULOUSE; (2) Ouvroir de toxicologie dispensaire, CHU, TOULOUSE;
Proclamation Mardi 15/04   10  P131 N Lechevallier (1); A Avant-coureur (1); C Berr (2); INCIDENCE OF BENZODIAZEPINE USE AND FACTORS ASSOCIATED WITH SUBSEQUENT USE IN THE ELDERLY: THE EVA STUDY
Abstract effectué
(1) Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) INSERM EMI-9930, Hosto de la Colombière, MONTPELLIER;
Proclamation Mardi 15/04   10  P132 A Avant-coureur (1); S De Bailliencourt (2); P Latry (2); C Peter (2); N Moore (1); B Bégaud (1); CHARACTERISTICS OF CELECOXIB PRESCRIPTIONS IN THE AQUITAINE REGION: DATA FROM THE REGIONAL DATABASE OF THE SECURITE SOCIALE
Abstract effectué
(1) Pharmacologie Asile, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) Sens Régionale Faveur médicinal certification malaise Aquitaine, Chemin de la Jallère, BORDEAUX;
Proclamation Mardi 15/04   10  P133 T Simon (1); A Chatelin (2); M Thuault (2); H Kolsky (3); P Jaillon (1); EPIFLEC : PHARMACO-EPIDEMIOLOGIC SURVEY OF FLECAINIDE TREATMENT IN A COHORT OF PATIENTS WITH ATRIAL FIBRILLATION
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Heureux-Antoine, AP-HP – UP6, PARIS; (2) MEDICAWEB, 67 rue Vergniaud, PARIS; (3) 3M SANTE, Bd de l’Oise, CERGY PONTOISE;
Proclamation Mardi 15/04   10  P134 N Lechevallier (1); A Avant-coureur (1); C Berr (2); PREVALENCE AND CHARACTERISTICS OF BENZODIAZEPINE USE IN THE ELDERLY: THE EVA STUDY
Abstract effectué
(1) Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) INSERM EMI-9930, Hosto de la Colombière, MONTPELLIER;
Proclamation Mardi 15/04   10  P135 S Rambelomanana (1); E Giauque (1); R Lagnaoui (1); A Abouelfath (1); P Brochard (2); I Futaie Valles (2); P Gabinski (2); B Bioulac (3); P Philip (3); N Moore (1); THE EFFECTS OF MEDICATION AND SLEEP ON WORKPLACE ACCIDENTS
Abstract effectué
(1) Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) Faveur de Purge du parturition, CHU de Pourpre, BORDEAUX; (3) Asile du anesthésie, CHU de Pourpre, BORDEAUX;
Proclamation Mardi 15/04   10  P136 M Lapeyre-Mestre (1); M Pin (1); PEDIATRIC COUNSELLING IN COMMUNITY PHARMACIES : KNOWLEDGE OF PHARMACISTS AND PHARMACY TECHNICIANS ABOUT DRUG UTILISATION IN CHILDREN
Abstract effectué
(1) Faveur de Pharmacologie Asile, Union de Pharmacoépidémiologie, Compréhension de Purge, TOULOUSE;
Proclamation Mardi 15/04   10  P137 E Polard (1); S Belliard (2); D Bentue-Attraper (3); P Le Cavorzin (4); R Duclos (1); AG Le Guen (1); MALAISE AND LOSS OF CONSCIOUSNESS IN DEMENTED PATIENTS TREATED BY ACETYLCHOLINESTERASE INHIBITORS
Abstract effectué
(1) Foyer de Pharmacovigilance, Hosto Pontchaillou, RENNES; (2) Faveur de Neurologie, Hosto Pontchaillou, RENNES; (3) Ouvroir de Pharmacologie Expérimentale et Asile, Compréhension de Purge, RENNES; (4) Foyer de Correction Fonctionnelle, Rennes, RENNES;
Proclamation Mardi 15/04   10  P138 T Ngoundo (1); M Niezborala (2); JL Montastruc (1); M Lapeyre-Mestre (1); PSYCHOACTIVE DRUG CONSUMPTION IN WORKERS AND PERFORMANCE AT WORK
Abstract effectué
(1) Union de Pharmacoépidémiologie, Faveur de Pharmacologie Asile, Compréhension de Purge, TOULOUSE; (2) Faveur Curatif Inter-Firmes, SMIT de Toulouse, TOULOUSE;
Proclamation Mardi 15/04   10  P139 P Bâtiment (1); F Pèze (1); P Cunin (2); N Elie (3); F Hemery (4); L Hittinger (5); I Masquin-Mavier (1); DRUG PRESCRIPTION AND REHOSPITALISATION RISK IN CHRONIC HEART FAILURE. LONGITUDINAL PHARMACOEPIDEMIOLOGICAL STUDY
Abstract effectué
(1) Faveur Pharmacologie Asile, Hopital Henri Mondor, CRETEIL; (2) Union de Mièvrerie Asile, Séminaire Paris XII, CRETEIL; (3) CPAM 94, Val de Poudrette, CRETEIL; (4) Departement Nouvelle Médicale, Hopital Henri Mondor, CRETEIL; (5) Ligue Cardiologie, Hopital Henri Mondor, CRETEIL;
Proclamation Mardi 15/04   10  P140 R Serreau (1); MF Le Heuzey (2); A Gilbert (1); YI Dubois (1); MC Mouren (2); E Jacqz-Aigrain (1); PSYCHOTROPIC MEDICATION IN CHILDREN : A FRENCH PROSPECTIVE SURVEY
Abstract effectué
(1) Pharmacology Unit, Lolo Debré Hospital, PARIS; (2) Psychopathology Unit, Lolo Debré Hospital, PARIS;
Proclamation Mardi 15/04   11  P141 G Naelten (1); B Chapuis (1); M Lo (1); J Sassard (1); LONG TERM EFFECTS OF RENIN-ANGIOTENSIN SYSTEM BLOCKADE IN GENETICALLY HYPERTENSIVE RATS OF THE LYON STRAIN (LH)
Abstract effectué
(1) CNRS UMR 5014, Compréhension de Remède, LYON;
Proclamation Mardi 15/04   11  P142 V Blessure (1); M Grima (2); P Kieffer (1); C Capdeville-Atkinson (1); J Atkinson (1); I Lartaud-Idjouadiene (1); WITHDRAWAL REVEALS LACK OF EFFECT OF PROLONGED ANTIHYPERTENSIVE TREATMENT ON INTRINSIC AORTIC WALL STIFFNESS IN SENESCENT SHR
Abstract effectué
(1) EA, 3448 / Compréhension de Remède, NANCY; (2) CNRS 0589, Compréhension de Purge, 11 rue Humann, STRASBOURG;
Proclamation Mardi 15/04   11  P143 JL Cracowski (1); JP Baguet (2); O Ormezzano (2); J Bessard (1); F Stanke-Labesque (1); G Bessard (1); JM Mallion (2); LIPID PEROXIDATION IS NOT INCREASED IN PATIENTS WITH UNTREATED MILD TO MODERATE HYPERTENSION
Abstract effectué
(1) Ouvroir de Pharmacologie, Compréhension de Purge, GRENOBLE; (2) Ligue des maladies cardio-vasculaires, CHU Grenoble, GRENOBLE;
Proclamation Mardi 15/04   11  P144 I Signolet (1); P Bousquet (1); L Monassier (1); EFFECTS OF THE CENTRALLY ACTING SYMPATHOINHIBITOR, RILMENIDINE, IN 1K1C GOLDBLATT HYPERTENSIVE RABBITS
Abstract effectué
(1) Ouvroir de Neurobiologie et Pharmacologie Cardiovasculaire, Compréhension de Purge, STRASBOURG;
Proclamation Mardi 15/04   11  P145 P Sassano (1); C Yau (1); E Ghannad (1); H Karam (1); B Fiquet (1); PROPULSION STUDY : TO ASSESS THE TOLERABILITY OF VALSARTAN (80 THEN 160 MG) IN MONOTHERAPY OVER 8 WEEKS IN HYPERTENSIVE PATIENTS AT HIGH CARDIOVASCULAR RISK
Abstract effectué
(1) Novartis Pharma SAS, 2-4 rue Lionel Terray, RUEIL MALMAISON;
Proclamation Mardi 15/04   11  P146 H Greney (1); D Urosevic (1); S Schann (1); L Dupuy (1); JD Ehrhardt (1); P Bousquet (1); A NEW RADIOACTIVE TOOL FOR INVESTIGATION OF I1 IMIDAZOLINE RECEPTORS
Abstract effectué
(1) Ouvroir de Neurobiologie et Pharmacologie Cardiovasculaire, Compréhension de Purge, STRASBOURG;
Proclamation Mardi 15/04   11  P147 H Masson (1); J Varagic (2); D Susic (2); E Frohlich (2); M Andréjak (1); M Slama (1); LEFT VENTRICULAR DIASTOLIC FUNCTION : ASSESSMENT IN SPONTANEOUS HYPERTENSIVE RAT (SHR)
Abstract effectué
(1) Cardiovascular physiopathology Lab, Compréhension de médicament UPJV, AMIENS; (2) Ochsner Clinic Foundation, NEW ORLEANS, USA;
Proclamation Mardi 15/04   11  P148 F Gueyffier (1); F Boutitie (2); JP Boissel (1); WHICH ARE THE RELEVANT QUESTIONS BEHIND THE RELATION BETWEEN A CONTINUOUS BIOMARKER AND A CLINICAL OUTCOME ? EXAMPLE OF BLOOD PRESSURE
Abstract effectué
(1) Faveur de Pharmacologie Asile, Compréhension RTH Laennec, LYON; (2) Faveur de Biostatistiques, Maternités Civils de Lyon, LYON;
Proclamation Mardi 15/04   12  P149 T Simon (1); M Mary-Krause (2); C Funck-Brentano (1); PH Lechat (3); P Jaillon (1); BISOPROLOL DOSE-RESPONSE RELATIONSHIP IN PATIENTS WITH CONGESTIVE HEART FAILURE
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Heureux-Antoine, AP-HP – UP6, PARIS; (2) INSERM EMI-0214, Hosto Compassion-Salpétrière, PARIS; (3) Faveur de Pharmacologie, Hosto Compassion-Salpétrière, PARIS;
Proclamation Mardi 15/04   12  P150 P Nony (1); E Amsallem (1); C Kasparian (1); G Haddour (1); JP Boissel (1); , For The Cardiodas Study Group (1); EVALUATION OF THE EFFECT OF PHOSPHODIESTERASE III INHIBITORS IN CHRONIC HEART FAILURE PATIENTS : AN UPDATED META-ANALYSIS
Abstract effectué
(1) EA 643, Hosto Cardiologique, LYON;
Proclamation Mardi 15/04   12  P151 N Mougenot (1); O Mediani (1); R Bos (1); F Brouri (1); P Lechat (1); CAPTOPRIL-FUROSEMIDE EFFECTS ON SURVIVAL ON THE EXPERIMENTAL MODEL OF HEART FAILURE IN THE RAT INDUCED BY MYOCARDIAL INFARCTION
Abstract effectué
(1) IFR 14 Pharmacology Department, Compassion Salpêtrière Hospital, PARIS;
Proclamation Mardi 15/04   12  P152 L Chauvelot-Moachon (1); L Fouqueray (2); C Vauzelle (1); F Bavoux (1); DOES PHARMACOLOGICAL STIMULATION OF RETINOIC ACID RECEPTORS AND RETINOID X RECEPTORS EXPOSE TO A RISK OF CARDIAC TOXICITY, AT TERM?
Abstract effectué
(1) Pharmacovigilance, Compréhension de Purge et Hosto Cochin, PARIS; (2) Cardiologie, Soisy sur Gabare, SOISY;
Proclamation Mardi 15/04   12  P153 P Mulder (1); V Mellin (1); A Jeng (1); JP Henry (1); C Thuillez (1); ADDTIVE EFFECTS OF TRIPLE ACE, ECE AND NEP INHIBITION ON HEMODYNAMICS, CARDIAC REMODELING AND FUNCTION IN RATS WITH CHRONIC HEART FAILURE
Abstract effectué
(1) INSERM E9920, Compréhension de Purge et de Remède, ROUEN;
Proclamation Mardi 15/04   13  P154 C Arnaud (1); JL Cracowski (1); A Hakim (1); T Durand (2); A Guy (2); D Godin-Ribuot (1); G Bessard (1); C Ribuot (1); ISOPROSTANES 15-F2T-ISOP AND 5-F2T-ISOP ARE NOT TRIGGERS OF MYOCARDIAL PRECONDITIONING
Abstract effectué
(1) Ouvroir de Pharmacologie, Compréhension de Purge, GRENOBLE; (2) Ouvroir de Chimie Biomoléculaire et Interactions Biologiques, UMR CNRS 5074, Compréhension de Remède de Montpellier, MONTPELLIER;
Proclamation Mardi 15/04   13  P155 K Aouam (1); R Tissier (1); R Souktani (1); A Berdeaux (1); B Ghaleh (1); MEASUREMENT OF POST-ISCHEMIC SYSTOLIC FUNCTION IN THE REPERFUSED HEART IN CONSCIOUS RABBITS: EFFECT OF PRECONDITIONING
Abstract effectué
(1) Ouvroir de Pharmacologie et INSERM E 00.01, Compréhension de Purge Paris Sud, LE KREMLIN-BICETRE;
Proclamation Mardi 15/04   13  P156 T Damy (1); A Bouzamondo (1); G Montalescot (2); P Lechat (1); SUPERIOR EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONNATED HEPARIN IN ACUTE CORONARY SYNDROMES WITHOUT ST ELEVATION
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Compassion-Salpêtrière, PARIS; (2) Faveur de Cardiologie, Hosto Compassion-Salpêtrière, PARIS;
Proclamation Mardi 15/04   13  P157 C Arnaud (1); M Spirituel (1); D Godin-Ribuot (1); JL Cracowski (1); C Ribuot (1); COX-2: AN IN VIVO EVIDENCE OF ITS PARTICIPATION TO HEAT STRESS-INDUCED MYOCARDIAL PRECONDITIONING
Abstract effectué
(1) Ouvroir Anoxie Physio-Pathologie, Compréhension de Remède, GRENOBLE;
Proclamation Mardi 15/04   14  P158 F Blanchi (1); N Ripoll (1); DJ David (1); M Hascoët (1); M Bourin (1); AN APPROPRIATE STRATEGY FOR SCREENING ANTIDEPRESSANT DRUGS USING THE MOUSE FORCED SWIMMING TEST AND THE TAIL SUSPENSION TEST
Abstract effectué
(1) EA 3256 Neurobiologie de l’appréhension et de la mélancolie, Compréhension de Purge, NANTES;
Proclamation Mardi 15/04   14  P159 D Tallet (1); P Del Soldato (2); M Bolla (2); N Oudart (1); NCX 950 (NO-SALBUTAMOL) SIGNIFICANTLY INHIBITS METHACHOLINE INDUCED BRONCHOCONSTRICTION AND REDUCES TACHYPHYLAXIS
Abstract effectué
(1) Ouvroir de Pharmacologie, Compréhension de Remède, LIMOGES; (2) Nicox SA, Avenue des Dolines, SOPHIA ANTIPOLIS;
Proclamation Mardi 15/04   14  P160 N Picard (1); D Ratanasavanh (2); Y Le Meur (3); A Rousseau (1); P Marquet (1); IN VITRO AND IN VIVO STUDY OF MYCOPHENOLIC ACID PHASE II METABOLISM
Abstract effectué
(1) Faveur de Pharmacologie et Toxicologie, CHU, LIMOGES; (2) Ouvroir de Pharmacologie, CHU Brest, BREST; (3) Faveur de urologie, CHU, LIMOGES;
Proclamation Mardi 15/04   14  P161 M Molimard (1); C Raherison (2); S Lignot (1); A Abouelfath (1); F Depont (1); N Moore (1); REAL-LIFE HANDLING OF INHALER DEVICES IN 3811 PATIENTS
Abstract effectué
(1) Préfecture de Pharmacologie, Séminaire Victor Segalen Pourpre 2, BORDEAUX; (2) Faveur des Maladies Respiratoires, Hosto Culminant Lévèque, PESSAC;
Proclamation Mardi 15/04   14  P162 G Ravel (1); M Christ (1); F Horand (1); J Descotes (2); EFFECT OF TWO PEDIATRIC VACCINES ON INSULIN-DEPENDENT DIABETES MELLITUS (IDDM) IN FEMALE NOD MICE
Abstract effectué
(1) MDS Pharma Tâches, Les Oncins, SAINT-GERMAIN-SUR-L’ARBRESLE; (2) Humeur Center, E. Herriot Hospital, LYON;
Proclamation Mardi 15/04   14  P163 M Mallem (1); V Bucas (1); F Gautier (1); M Gogny (1); J Desfontis (1); BETA3 AND ATYPICAL BETA-ADRENOCEPTORS IN HYPERTENSION
Abstract effectué
(1) UPSP5304, Ecole Vétérinaire, NANTES;
Proclamation Mardi 15/04   14  P164 PA Risse (1); E Naline (1); G Huchon (2); C Advenier (1); N Afrique (2); ROLE OF PAR-2 IN THE REGULATION OF AIRWAY SMOOTH MUSCLE (SM) TONE
Abstract effectué
(1) UPRES EA220, UFR Biomédicale des Saints Pères, PARIS; (2) Faveur de Phtisiologie et de Ranimation, Hosto de l’Arrêt Logos, PARIS;
Proclamation Mardi 15/04   14  P165 A Appert-Collin (1); A Lebon (1); P Poindron (1); JP Ges (1); CELL CYCLE REGULATORS IN MOTONEURONAL DEATH EVOKED BY NEUROTROPHIC FACTOR DEPRIVATION
Abstract effectué
(1) LPCCNM, Compréhension de capsule, ILLKIRCH;
Proclamation Mardi 15/04   14  P166 C Pascarel (1); A- El Amrani (1); K Viaud (1); R Dalonneau (1); C Champeroux (1); S Richard (1); HERG TRANSFECTED HEK-293 CELLS: A PHARMACOLOGICAL TOOL FOR DRUG ASSESSMENT OF QT INTERVAL PROLONGATION
Abstract effectué
(1) CERB, Berme de Montifault, BAUGY;
Proclamation Mardi 15/04   14  P167 M Forteresse (1); O Pétrault (2); L Gruand (2); M Laprais (2); S Stolc (3); R Bordet (2); PROTECTIVE EFFECTS OF STOBADINE, AN ANTIOXIDANT AGENT, ON NEURONAL AND VASCULAR ALTERATIONS INDUCED BY ISCHEMIA/REPERFUSION (I/R) ON RAT
Abstract effectué
(1) IUT A, Séminaire de Lille 1, VILLENEUVE D’ASCQ; (2) Ouvroir de Pharmacologie, Compréhension de Purge de Lille 2, LILLE; (3) Université de Pharmacologie Expérimentale, Institut Slovaque des Sciences, BRATISLAVA, SLOVAQUIE;
Proclamation Mercredi 16/04   15  P168 C Verstuyft (1); M Schwab (2); E Schaeffeler (2); R Kerb (3); U Brinkmann (3); P Jaillon (1); C Funck-Brentano (1); L Becquemont (1); DIGOXIN PHARMACOKINETICS AND MDR1 GENETIC POLYMORPHISMS
Abstract effectué
(1) Pharmacologie, Compréhension de médicament Heureux-Antoine, PARIS; (2) Dr. Margarete Fischer-Bosch-Université für Klinische Pharmakologie, Lolo Bosch foundation, STUTTGART, ALLEMAGNE; (3) Epidauros Biotechnologie, Epidauros Biotechnologie, BERNRIED, ALLEMAGNE;
Proclamation Mercredi 16/04   15  P169 S Morin (1); MA Grive dorée (2); HK Thijssen (3); A Lolo (4); S Strabach (5); C Verstuyft (1); L Dubert (1); C Funck-Brentano (5); P Jaillon (1); PH Beaune (2); L Becquemont (1); VARIATIONS OF INR AND FACTOR VII ARE LINKED TO CYTOCHROME P450 2C9 GENOTYPE
Abstract effectué
(1) Faveur de Pharmacologie, Compréhension de médicament Heureux-Antoine, PARIS; (2) INSERM U 490, Séminaire Paris V, PARIS; (3) Faveur de Pharmacologie, Séminaire de Maastricht, MAASTRICHT, PAYS-BAS; (4) Faveur d’coagulation, CHU Heureux-Antoine, PARIS; (5) Foyer d’enquête dispensaire, CHU Heureux-Antoine, PARIS;
Proclamation Mercredi 16/04   15  P170 T Damy (1); F Pousset (2); H Caplain (3); JS Hulot (1); PH Lechat (1); PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS BETWEEN METOPROLOL AND DRONEDARONE IN HEALTHY SUBJECTS
Abstract effectué
(1) Faveur de Pharmacologie, Hosto Compassion-Salpétrière, PARIS; (2) Faveur de Cardiologie, Hosto Compassion-Salpétrière, PARIS; (3) Aster Clinical Research Center, 3-5 rue Eugène Millon, PARIS;
Proclamation Mercredi 16/04   15  P171 D Zhang (1); C Ganière-Monteil (2); Y Médard (1); M Bourin (2); E Jacqz-Aigrain (1); PHENOTYPE AND GENOTYPE FOR THIOPURINE METHYLTRANSFERASE ACTIVITY IN THE FRENCH CAUCASIAN POPULATION: IMPACT OF AGE
Abstract effectué
(1) Pharmacologie Pédiatrique – Pharmacogénétique, Hosto Lolo Debré, PARIS; (2) Pharmacologie, Hosto Arrêt-Logos, NANTES;
Proclamation Mercredi 16/04   15  P172 M Fakhoury (1); R Serreau (1); Y Medard (1); AL Delezoide (2); E Jacqz-Aigrain (1); REAL TIME QUANTITATIVE RT-PCR OF CYP3A IN PLACENTA
Abstract effectué
(1) Pharmacology Unit, Lolo Debré Hospital, PARIS; (2) Foetopathology unit, Lolo Debré Hospital, PARIS;
Proclamation Mercredi 16/04   15  P173 JM Poirier (1); O Zouai (1); JL Meynard (2); K Lacombe (2); PM Girard (2); P Jaillon (1); LACK OF EFFECT OF GENDER, AGE, WEIGHT AND BODY MASS INDEX ON TROUGH LOPINAVIR PLASMA CONCENTRATIONS IN HIV-EXPERIENCED PATIENTS TREATED WITH KALETRA
Abstract effectué
(1) Department of pharmacology, Heureux-Antoine University Hospital, PARIS; (2) Department of Infectious Diseases, Heureux-Antoine Hospital, PARIS;
Proclamation Mercredi 16/04   15  P174 S Laporte (1); B Tranchand (2); A Viallon (3); M Ollagnier (4); M Cucherat (5); C Guy (4); H Décousus (1); P Mismetti (1); POOLING OF INDIVIDUAL TOXICOKINETIC CASE REPORTS USING A POPULATION APPROACH MODEL
Abstract effectué
(1) Union de Pharmacologie Asile, EA3065, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (2) Foyer Léon Bérard, Rue Laënnec, LYON; (3) Faveur d’Asile des Urgences, EA3065, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (4) Union de Pharmacologie et Toxicologie, CHU Heureux-Etienne Bellevue, SAINT-ETIENNE; (5) EA 643 Compréhension RTH Laennec, Faveur de Biostatistiques, CHU Lyon, LYON;
Proclamation Mercredi 16/04   15  P175 F Stanke-Labesque (1); S Larrat (1); G Bessard (1); JP Zarski (2); C Souvignet (2); RIBAVIRIN QUANTIFICATION FOR THERAPEUTIC DRUG MONITORING DURING CHRONIC HEPATITIS C COMBINATION TREATMENT
Abstract effectué
(1) Ouvroir de Pharmacologie, CHU Grenoble, GRENOBLE; (2) Préfecture d’hépato-gastroentérologie, CHU Grenoble, GRENOBLE;
Proclamation Mercredi 16/04   15  P176 N Simon (1); G Slepchenko (2); O Pérus (2); JC Levron (3); M Raucoules-Aimé (2); B Bruguerolle (1); POPULATION PHARMACOKINETICS OF SUFENTANIL IN OBESE PATIENTS
Abstract effectué
(1) Ouvroir de Pharmacologie médicale et dispensaire, Compréhension de médicament, MARSEILLE; (2) Préfecture d’anesthésie-réanimation, Hosto l’Baguette 2, NICE; (3) Ouvroir Janssen Cilag, Janssen Research Base, VAL DE REUIL;
Proclamation Mercredi 16/04   15  P177 N Simon (1); F Lacroix (2); E Deturmeny (1); O Paut (2); J Camboulives (2); B Bruguerolle (1); COMPARATIVE PHARMACOKINETICS OF 0.2 VS 0.375 % ROPIVACAINE DURING FASCIA ILIACA COMPARTMENT BLOCK IN CHILDREN
Abstract effectué
(1) Ouvroir Pharmacologie médicale et dispensaire, Compréhension de médicament, MARSEILLE; (2) Departement d’narcose Ranimation Pédiatrique, CHU Timone, MARSEILLE;
Proclamation Mercredi 16/04   15  P178 P Nony (1); JP Boissel (1); PREDICTING DRUG FORGIVENESS: A STANDARDISED GRAPHICAL APPROACH
Abstract effectué
(1) EA 643, Hosto Cardiologique, LYON;
Proclamation Mercredi 16/04   15  P179 E Dailly (1); M Pannier (2); P Jolliet (1); M Bourin (1); POPULATION PHARMACOKINETICS OF CEFTAZIDIME IN BURN PATIENTS
Abstract effectué
(1) Ouvroir de Pharmacologie, Arrêt Logos, NANTES; (2) Faveur des Brûlés, Arrêt Logos, NANTES;
Proclamation Mercredi 16/04   15  P180 S Payen (1); R Serreau (2); A Munck (3); Y Aujard (4); Y Aigrain (5); F Bressolle (1); E Jacqz-Aigrain (2); POPULATION PHARMACOKINETICS OF CIPROFLOXACIN IN PEDIATRIC AND ADOLESCENT PATIENTS WITH ACUTE INFECTIONS
Abstract effectué
(1) Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, MONTPELLIER; (2) Paediatric Pharmacology and Pharmacogenetics, Lolo Debré Hospital, PARIS; (3) Gastro-Enterology, Lolo Debré Hospital, PARIS; (4) Neonatologie, Lolo Debré Hospital, PARIS; (5) Paediatric Surgery, Lolo Debré Hospital, PARIS;
Proclamation Mercredi 16/04   15  P181 C Verstuyft (1); F Marcellin (2); L Morand-Joubert (3); O Launay (4); G Peytavin (5); L Gerard (2); L Becquemont (6); JP Aboulker (2); For The Anrs 081 (7); IMPACT OF MDR1 (C3435T) GENETIC POLYMORPHISM IN PATIENTS NAÏVE TREATED WITH HAART INCLUDING INDINAVIR (IDV)
Abstract effectué
(1) Pharmacology Department, Faculty of medecine, PARIS; (2) SC 10, Villejuif, VILLEJUIF; (3) Virology Department, Heureux-Antoine Hospital, PARIS; (4) Infectious Disease Department, Bichat-Claude Bernard, PARIS; (5) Pharmacy Department, Bichat-Claude Bernard, PARIS; (6) Pharmacology Department, Heureux-Antoine Hospital, PARIS; (7) ANRS, PARIS;
Proclamation Mercredi 16/04   15  P182 X Zhang (1); V Favier (2); JM Lang (3); J Reynes (4); D Rey (3); R Rouzier-Panis (5); M Botteler (2); E Gaudeul-Ehrhart (2); P Desche (2); I Patel (1); PHARMACOKINETICS OF HIV FUSION INHIBITOR T-20 (FUZEON) AFTER BOTH INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) ADMINISTRATION TO HIV-1 INFECTED PATIENTS
Abstract effectué
(1) Clinical pharmacology dpt, Hoffmann-La ROCHE Inc., NUTLEY, USA; (2) Université de Pharmacologie Asile ROCHE, Hosto Obligeant de Strasbourg, STRASBOURG; (3) Secours d’Immuno-Onco-Hematologie, Hosto Obligeant de Strasbourg, STRASBOURG; (4) Faveur des Maladies Infectueuses et Tropicales, Hosto Gui de Chauliac, MONTPELLIER; (5) Foyer CAP, Asile Rech, MONTPELLIER;
Proclamation Mercredi 16/04   15  P183 E Caudron (1); V Jullien (1); C Amrein (2); R Guillemain (2); P Chevallier (2); C Le Beller (1); A Lillo-Le Louet (1); EM Billaud (1); TACROLIMUS THERAPEUTIC DRUG MONITORING (TDM) IN THE MANAGEMENT OF DRUG INTERACTION WITH VORICONAZOLE IN PULMONARY TRANSPLANTATION
Abstract effectué
(1) Pharmacologie Toxicologie, HEGP, PARIS; (2) Opération Cardio Vasculaire, HEGP, PARIS;
Proclamation Mercredi 16/04   15  P184 O Cens (1); C Mince (2); C Arvieux (3); H Allain (1); D Bentué-Attraper (1); TACROLIMUS AND PROTEASE INHIBITORS INTERACTION IN PATIENTS WITH LIVER TRANSPLANTATION
Abstract effectué
(1) Ouvroir de Pharmacologie Expérimentale et Asile, Compréhension de Purge, RENNES; (2) Faveur de Ranimation Médicale, Hosto Pontchaillou, RENNES; (3) Faveur des Maladies Infectieuses, Hosto Pontchaillou, RENNES;
Proclamation Mercredi 16/04   15  P185 N Ferrari (1); S Aggloméré (1); P Odou (2); L Kroumova (1); C Lamotte (1); J Wiart (3); P Devos (4); M Lhermitte (3); C Libersa (1); NIFEDIPINE AND GRAPEFRUIT JUICE: FACT OR FICTION ?
Abstract effectué
(1) CIC Lille, CHRU LILLE, LILLE; (2) Préfecture de biopharmacie et de capsule dispensaire, Compréhension de Remède, LILLE; (3) Ouvroir de biochimie et de génétique moléculaire, CHRU LILLE, LILLE; (4) D.I.M., CHRU LILLE, LILLE;
Proclamation Mercredi 16/04   15  P186 B Guillet (1); B Bordas (1); R Purgus (2); B Dussol (2); A Durand (1); Y Berland (2); P Pisano (1); PHARMACOKINETICS OF MYCOPHÉNOLIC ACID (MPA) TOTAL AND FREE IN RENAL TRANSPLANT PATIENTS WITH CHRONIC GRAFT DYSFUNCTION
Abstract effectué
(1) Ligue de Pharmacologie, CHU Timone, 254 rue St Solitaire, MARSEILLE; (2) Faveur de Urologie, CHU Élaboration, 170 bd Cuve, MARSEILLE;
Proclamation Mercredi 16/04   15  P187 Y Hijazi (1); R Boulieu (2); CONTRIBUTION OF CYP3A4, CYP2B6, AND CYP2C9 ISOFORMS TO N-DEMETHYLATION OF KETAMINE IN HUMAN LIVER MICROSOMES
Abstract effectué
(1) PDMP, Hoffmann-La Afrique, BASEL, SWITZERLAND; (2) Ouvroir de Pharmacocinétique Asile, Séminaire de Lyon 1, LYON;
Proclamation Mercredi 16/04   16  P188 P Meshaka (1); N Mouchet (2); C Gaillez (1); S Rien (3); D Muzard (3); P Pinton (1); TREATMENT OF SEVERE SEPSIS WITH 2 ORGAN FAILURES – TEMPORARY AUTHORIZATION OF USE (TAU) OF XIGRIS IN ADULTS AND CHILDREN
Abstract effectué
(1) Union Médicinal Cardiologie, Infectiologie et Ranimation, Lilly France, SURESNES; (2) Préfecture des Finance Conformes, Lilly France, SURESNES; (3) Préfecture de Pharmacovigilance, Lilly France, SURESNES;
Proclamation Mercredi 16/04   16  P189 K Lacut (1); E Oger (1); G Le Gal (1); F Couturaud (1); S Paillette (2); C Leroyer (1); D Mottier (1); STATIN USE IS ASSOCIATED WITH A REDUCED RISK FOR VENOUS THROMBOEMBOLISM
Abstract effectué
(1) Préfecture de Purge Foyer et Phtisiologie, CHU Mulassière Livide, BREST; (2) Union d’Echo-Doppler, CHU Mulassière Livide, BREST;
Proclamation Mercredi 16/04   16  P190 S Dias (1); M Cucherat (1); E Amsallem (1); JP Boissel (1); ACCEPTABILITY BY GPS OF A NEW APPROACH OF KNOWLEDGE TRANSFER IN THERAPEUTICS
Abstract effectué
(1) EA 643, Compréhension de médicament RTH Laennec, LYON;
Proclamation Mercredi 16/04   16  P191 M Daurel-Débitant (1); S Picard (1); K Titier (1); D Ducint (1); F Pehourcq (1); N Moore (1); M Molimard (1); FULLY AUTOMATED ANALYTICAL METHOD FOR MYCOPHENOLIC ACID QUANTIFICATION IN HUMAN PLASMA USING ON-LINE SOLID PHASE EXTRACTION AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION
Abstract effectué
(1) Ouvroir de pharmacologie dispensaire et de toxicologie, Séminaire V. Segalen, CHU Pellegrin, BORDEAUX;
Proclamation Mercredi 16/04   16  P192 M Cucherat (1); E Amsallem (1); JP Boissel (1); TRIALYS : A KNOWLEDGE DATABASE OF CLINICAL TRIALS RESULTS
Abstract effectué
(1) EA 643, Compréhension de Purge Laennec, LYON;
Proclamation Mercredi 16/04   16  P193 S Belgun – florea (1); S Briançon (2); J Doury (1); H Fessi (2); DEVELOPMENT OF A NEW PHARMACEUTICAL FORMULATION EFFECTIVE IN PREVENTION AND/OR TREATMENT OF DENTO-PERIODONTAL DISEASES
Abstract effectué
(1) Ouvroir de exploration en sensualité confirmée (Lass – UMR 5823 CNRS), Compréhension d’orthodontie, 11 rue Doucine Parradin, LYON; (2) Ouvroir d’Inné et de Cacique des Procédés (Lagep-UMR 5007CNRS), Univ. C. Bernard Lyon1, 43 bd du 11 brumaire 1918, VILLEURBANNE;
Proclamation Mercredi 16/04   16  P194 AN Barkun (1); V Adam (2); W Kennedy (3); CA Fallone (1); K Herba (1); M Bardou (1); THE COST-EFFECTIVENESS OF HIGH DOSE ORAL VERSUS INTRAVENOUS PROTON PUMP INHIBITION IN HIGH-RISK PATIENTS WITH BLEEDING PEPTIC ULCERS HAVING UNDERGONE THERAPEUTIC ENDOSCOPY
Abstract effectué
(1) Gastroenterology Department, McGill University Health Center, MONTREAL, CANADA; (2) Bouchée of epidemiology, McGill University, MONTREAL, CANADA; (3) Compréhension de capsule, Séminaire de Montréal, MONTREAL, CANADA;
Proclamation Mercredi 16/04   16  P195 P Nicolas (1); B Uzzan (1); M Cucherat (2); JP Boissel (2); GY Perret (1); THE ROLE OF MICROVESSEL DENSITY (MVD) ON THE SURVIVAL OF PATIENTS WITH BREAST CARCINOMA : A SYSTEMATIC REVIEW OF THE LITERATURE WITH META-ANALYSIS
Abstract effectué
(1) Lab Pharmacologie, Compréhension de Purge – CHU Bobigny, BOBIGNY; (2) Lab Pharmacologie, Compréhension de Purge – Séminaire Lyon 1, LYON;
Proclamation Mercredi 16/04   17  P196 S Oger (1); C Mehats (2); E Dallot (1); F Protégé (1); D Cabrol (1); MJ Leroy (1); UTERO-RELAXANT AND ANTI-INFLAMMATORY PROPERTIES OF SELECTIVE PDE4 (cAMP-SPECIFIC PHOSPHODIESTERASES) INHIBITORS IN HUMAN MYOMETRIUM
Abstract effectué
(1) INSERM U361, Dispensaire Étape Opulent Cochin, Séminaire Paris 5, PARIS; (2) Bouchée of Reproductive Biology, Stanford University School of Medicine, STANFORD, ETATS-UNIS;
Proclamation Mercredi 16/04   17  P197 C Aoûtat (1); MJ Leroy (2); M Breuiller-Fouché (2); C Loustalot (3); E Morcillo (4); T Croci (5); E Naline (1); F Protégé (2); C Advenier (1); M Bardou (1); ABSENCE OF DESENSITISATION OF BETA 3 ADRENERGIC RESPONSE IN HUMAN NEAR-TERM MYOMETRIUM
Abstract effectué
(1) UPRES EA220, UFR Biomédicale des Saints Pères, PARIS; (2) INSERM U361, Mirador Baudelocque, PARIS; (3) CHU du Garenne, Dijon, DIJON; (4) Préfecture de Pharmacologie, Séminaire de Valence, VALENCE, ESPAGNE; (5) Foyer de exploration Sanofi-Midy, Milan, MILAN, ITALIE;
Proclamation Mercredi 16/04   17  P198 N Geffroy (1); A Guédin (1); P Formstecher (1); C Dacquet (2); P Lefebvre (1); CHARACTERIZATION OF NON GENOMIC EFFECTS OF ESTROGENS IN HELA AND MCF7 CELLS
Abstract effectué
(1) INSERM U459, Compréhension de Purge H Warembourg, LILLE; (2) Université de Recherches Servier, IRIS, COURBEVOIE;
Proclamation Mercredi 16/04   17  P199 M Sarr (1); JC Alencar (1); JC Stoclet (1); VB Schini-Kerth (1); B Muller (2); LONG-LASTING INHIBITION OF ARTERIAL TONE BY NO IN VARIOUS VASCULAR BEDS: DIFFERENTIAL INFLUENCE OF THE ENDOTHELIUM
Abstract effectué
(1) UMR 7034, Compréhension de Remède, STRASBOURG; (2) INSERM 9937, UFR Sciences Pharmaceutiques & EMI, BORDEAUX;
Proclamation Mercredi 16/04   17  P200 K Père (1); N Simon (1); B Bruguerolle (1); EFFECTS OF CHLORPYRIFOS ON OXIDATIVE PHOSPHORYLATION OF ISOLATED RAT MITOCHONDRIA
Abstract effectué
(1) Ouvroir de Pharmacologie médicale et dispensaire, Compréhension de médicament, MARSEILLE;
Proclamation Mercredi 16/04   17  P201 B Guillet (1); L Velly (1); S Lortet (2); F Masmejean (2); A Nieoullon (2); P Pisano (1); REGULATION OF ACTIVITY AND CELL SURFACE EXPRESSION OF GLUTAMATE TRANSPORTERS IN NEURON-ENRICHED CULTURES REQUIRES PHOSPHORYLATION
Abstract effectué
(1) Ouvroir de pharmacodynamie, UFR Remède, 27 bd Pantalon Maillotin, MARSEILLE; (2) LNCF, FRE CNRS 2131, 31 Berme Joseph Aiguier, MARSEILLE;
Proclamation Mercredi 16/04   17  P202 L Favot (1); T Keravis (1); V Holl (2); C Lugnier (1); INVOLVEMENT OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES (PDES) IN ANGIOGENESIS
Abstract effectué
(1) UMR CNRS 7034, Compréhension de capsule, ILLKIRCH; (2) Ouvroir de Carcinologie Expérimentale et de Radiobiologie (LCER), IRCAD, STRASBOURG;
Proclamation Mercredi 16/04   17  P203 A Maguy (1); D Godreau (1); R Vranckx (1); C Goyenvalle (1); S Hatem (1); SAP-97 PROMOTES HKV1.5 COMPARTMENTATION TO LIPID RAFTS AND INTERACTION WITH BETA-SUBUNIT: CONSEQUENCES ON CURRENTS PROPERTIES
Abstract effectué
(1) U460 INSERM, Compréhension de médicament X. BICHAT, PARIS;
Proclamation Mercredi 16/04   17  P204 A Maguy (1); S Hatem (1); D Godreau (1); NEW PROCEDURE TO REALISE CELL LINE STABLY EXPRESSING A CLONED PROTEIN
Abstract effectué
(1) U460 INSERM, Compréhension de médicament X. BICHAT, PARIS;
Proclamation Mercredi 16/04   17  P205 C Moro (1); J Galitzky (1); C Sengenès (1); F Crampes (1); M Lafontan (1); M Berlan (1); EVALUATION OF ANP-INDUCED LIPOLYSIS ANTAGONISTS IN HUMAN ADIPOSE TISSUE.
Abstract effectué
(1) INSERM U317, Compréhension de Purge, TOULOUSE;
Proclamation Mercredi 16/04   17  P206 C Labrande (1); F Masmejean (2); S Lortet (2); A Nieoullon (2); P Pisano (1); NEUROPROTECTIVE EFFECTS OF TACROLIMUS DURING IN VITRO CEREBRAL ISCHEMIA : INSIGHTS ON THE ROLE OF GLUTAMATE
Abstract effectué
(1) Ouvroir pharmacodynamie, Compréhension Remède 27 bd Pantalon Maillotin, MARSEILLE; (2) FRE CNRS 2131, 31 Berme Joseph Aiguier, MARSEILLE;
Proclamation Mercredi 16/04   18  P207 C Brefel-Courbon (1); P Payoux (2); C Thalamas (3); I Quelven (2); M Galitzky (3); JL Montastruc (1); JP Esquerre (2); F Chollet (4); O Rascol (1); LEVODOPA EFFECT ON EXPERIMENTAL PAIN IN PARKINSON’S DISEASE: A CLINICAL AND NEUROIMAGING PILOT STUDY
Abstract effectué
(1) Faveur de Pharmacologie, INSERM U455, Compréhension de Purge, TOULOUSE; (2) Faveur de medecine atomique INSERM U455, CHU Purpan, TOULOUSE; (3) Foyer d’enquête dispensaire, CHU Purpan, TOULOUSE; (4) INSERM U455, CHU Purpan, TOULOUSE;
Proclamation Mercredi 16/04   18  P208 J Micallef (1); S Tardieu (1); S Durand (1); G Masson (2); D Mestre (2); O Blin (1); EFFECTS OF A SUBANESTHETIC DOSE OF KETAMINE ON SACCADIC EYE MOVEMENTS IN HEALTHY SUBJECTS
Abstract effectué
(1) CPCET & Université de Neurosciences Physiologiques et Cognitives, CHU Timone, MARSEILLE; (2) Foyer de Recherches en Neurosciences Cognitives, CNRS, MARSEILLE;
Proclamation Mercredi 16/04   18  P209 O Rascol (1); D Brooks (2); W Olanow (3); G Koch (4); PH Truffinet (5); R Bejuit (5); The Riluzole 320 Study Group (6); THE EFFECT OF RILUZOLE ON PARKINSON’S DISEASE PROGRESSION : A 2-YEAR TRIAL
Abstract effectué
(1) Faveur de Pharmacologie, INSERM U455, Compréhension de Purge, TOULOUSE; (2) Hammersmith Hospital, MRC Synchrotron Unit, LONDON, UK; (3) Mount Sinai, Medical Center, NEW YORK, USA; (4) Biostatistics Department, Chapel Hill, CHAPEL HILL, USA; (5) Aventis, ANTONY; (6) 122 Investigators from eleven countries, INTERNATIONAL;
Proclamation Mercredi 16/04   18  P210 H Allain (1); D Bentue-Attraper (1); A Tarral (2); O Cens (1); E Polard (3); JM Gandon (2); EFFECTS ON POSTURAL OSCILLATION AND MEMORY FUNCTIONS OF A SINGLE DOSE OF ZOLPIDEM 5MG, ZOPICLONE 3.75MG AND LORMETAZEPAM 1MG IN ELDERLY HEALTHY SUBJECTS
Abstract effectué
(1) Ouvroir de Pharmacologie Expérimentale et Asile, Compréhension de Purge, RENNES; (2) BIOTRIAL S.A., Atalante Villejean, RENNES; (3) Foyer de Pharmacovigilance, Hosto Pontchaillou, RENNES;
Proclamation Mercredi 16/04   18  P211 G Pickering (1); V Batel (1); A Eschalier (1); C Dubray (1); ANALGESICS CONSUMPTION AND ALZHEIMER’S DISEASE
Abstract effectué
(1) INSERM EMI 9904 Ouvroir de Pharmacologie Médicale, Compréhension de Purge BP38 CHU, CLERMONT-FERRAND;
Proclamation Mercredi 16/04   19  P212 C Sévoz-Lange (1); MA Comet (1); M Hamon (1); R Laguzzi (1); INVOLVEMENT OF NUCLEUS TRACTUS SOLITARIUS (NTS) 5-HT3 AND GABAA RECEPTORS IN THE DEFENSE REACTION-INDUCED INHIBITION OF AORTIC BAROREFLEX BRADYCARDIA IN THE RAT
Abstract effectué
(1) INSERM U288, Compréhension de médicament Compassion-Salpêtrière, PARIS;
Proclamation Mercredi 16/04   19  P213 A Kreisler (1); P Glaçon (2); A Destée (1); R Bordet (2); NEUROPROTECTIVE EFFECT OF PPAR-ALPHA AGONIST IN THE MPTP MOUSE MODEL OF PARKINSON’S DISEASE
Abstract effectué
(1) EA 2643, Neurologie A, CHRU, LILLE; (2) EA 1046, Pharmacologie, Compréhension de Purge, LILLE;
Proclamation Mercredi 16/04   19  P215 V Lelong (1); F Cachalot (2); M Boulouard (1); LOCALIZATION OF 5-HT4 RECEPTORS IMPLICATED IN WORKING MEMORY IN MICE: EFFECT OF SEROTONERGIC LESIONS ON BEHAVIOURAL AND NEUROCHEMICAL (BINDING SITES DENSITY) PARAMETERS
Abstract effectué
(1) UPRES EA 2126, Compréhension de Remède, Séminaire de Caen, CAEN; (2) UMR 6551, Séminaire de Caen, CAEN;
Proclamation Mercredi 16/04   19  P216 H Legros (1); F Janin (1); N Dourmap (1); JJ Gésier (1); J Costentin (1); SEMI-CHRONIC INCREASE IN STRIATAL LEVEL OF 3,4-DIHYDROXYPHENYLACETALDEHYDE DOES NOT RESULT IN ALTERATION OF NIGRO-STRIATAL DOPAMINERGIC NEURONS
Abstract effectué
(1) Union de NeuroPsychoPharmacologie Expérimentale UMR 6036 CNRS, Compréhension de Purge et de Remède, ROUEN;
Proclamation Mercredi 16/04   19  P217 P Bredeloux (1); A Tabarly (1); I Dubuc (1); J Martinez (2); J Costentin (1); MICE MADE TOLERANT TO MORPHINE ANALGESIA ARE ALSO TOLERANT TO THE ANALGESIC EFFECT OF A CYCLIC ANALOG OF NEUROTENSIN
Abstract effectué
(1) UMR 6036 CNRS, Union de neuropsychopharmacologie expérimentale, IFRMP23, Compréhension de Purge et de Remède, ROUEN; (2) Ouvroir des Aminoacides, peptides et protéines ESA 5075, Compréhension de capsule, MONTPELLIER;
Proclamation Mercredi 16/04   19  P218 MA Comet (1); C Sévoz-Lange (1); M Hamon (1); R Laguzzi (1); ACTIVATION OF THE PERIAQUEDUCTAL GRAY MATTER INHIBITS THE CARDIAC COMPONENT OF THE BARORECEPTOR REFLEX VIA STIMULATION OF 5-HT3 RECEPTORS IN THE RAT NUCLEUS TRACTUS SOLITARIUS
Abstract effectué
(1) INSERM U288, Compréhension de médicament Compassion-Salpêtrière, PARIS;
Proclamation Mercredi 16/04   19  P219 JP Guilloux (1); C Przybylski (1); F Artigas (2); M Toth (3); AM Gardier (1); EFFECT OF COADMINISTRATION OF PAROXETINE AND (±)-PINDOLOL ON EXTRACELLULAR SEROTONIN : A NOVEL APPROACH USING KO 5-HT1A MICE
Abstract effectué
(1) EA 3544 Lab. Neuropharmacologie, Compréhension de Remède Séminaire Paris-Sud, CHATENAY-MALABRY; (2) Departement of Neurochemistry, Université d’Investigacions Biomediques, BARCELONA, SPAIN; (3) Department of pharmacology, Weill Medical College of Cornell University, NEW YORK, USA;
Proclamation Mercredi 16/04   19  P220 J Tailleur (1); N Croci (1); M Plotkine (1); I Margaill (1); 3-AMINOBENZAMIDE, A POLY(ADP-RIBOSE) POLYMERASE INHIBITOR, REDUCES BRAIN INFARCTION AND POLYMORPHONUCLEAR NEUTROPHIL INFILTRATION AFTER CEREBRAL ISCHEMIA/REPERFUSION IN MICE
Abstract effectué
(1) Ouvroir de Pharmacologie UPRES EA2510, Séminaire René Descartes Paris V, PARIS;

Feuillet précédente